<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70151</article-id><article-id pub-id-type="doi">10.7554/eLife.70151</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>A zebrafish embryo screen utilizing gastrulation identifies the HTR2C inhibitor pizotifen as a suppressor of EMT-mediated metastasis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nakayama</surname><given-names>Joji</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1077-140X</contrib-id><email>zmetastasis@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Lora</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Goh</surname><given-names>Boon Cher</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Makinoshima</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gong</surname><given-names>Zhiyuan</given-names></name><email>dbsgzy@nus.edu.sg</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biological Science, National University of Singapore</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff2"><label>2</label><institution>Cancer Science Institute of Singapore, National University of Singapore</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff3"><label>3</label><institution>Tsuruoka Metabolomics Laboratory, National Cancer Center</institution><addr-line><named-content content-type="city">Tsuruoka</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution>Shonai Regional Industry Promotion Center</institution><addr-line><named-content content-type="city">Tsuruoka</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution>Institute of Bioengineering and Nanotechnology</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff6"><label>6</label><institution>Division of Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center</institution><addr-line><named-content content-type="city">Kashiwa</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shimada</surname><given-names>Yasuhito</given-names></name><role>Reviewing Editor</role><aff><institution>Mie University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Heart and Lung Research</institution><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>12</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e70151</elocation-id><history><date date-type="received" iso-8601-date="2021-05-07"><day>07</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-17"><day>17</day><month>12</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-03-05"><day>05</day><month>03</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.04.434001"/></event></pub-history><permissions><copyright-statement>© 2021, Nakayama et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Nakayama et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70151-v4.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-70151-figures-v4.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.76632" id="ra1"/><abstract><p>Metastasis is responsible for approximately 90% of cancer-associated mortality but few models exist that allow for rapid and effective screening of anti-metastasis drugs. Current mouse models of metastasis are too expensive and time consuming to use for rapid and high-throughput screening. Therefore, we created a unique screening concept utilizing conserved mechanisms between zebrafish gastrulation and cancer metastasis for identification of potential anti-metastatic drugs. We hypothesized that small chemicals that interrupt zebrafish gastrulation might also suppress metastatic progression of cancer cells and developed a phenotype-based chemical screen to test the hypothesis. The screen used epiboly, the first morphogenetic movement in gastrulation, as a marker and enabled 100 chemicals to be tested in 5 hr. The screen tested 1280 FDA-approved drugs and identified pizotifen, an antagonist for serotonin receptor 2C (HTR2C) as an epiboly-interrupting drug. Pharmacological and genetic inhibition of HTR2C suppressed metastatic progression in a mouse model. Blocking HTR2C with pizotifen restored epithelial properties to metastatic cells through inhibition of Wnt signaling. In contrast, HTR2C induced epithelial-to-mesenchymal transition through activation of Wnt signaling and promoted metastatic dissemination of human cancer cells in a zebrafish xenotransplantation model. Taken together, our concept offers a novel platform for discovery of anti-metastasis drugs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>metastasis</kwd><kwd>gastrulation</kwd><kwd>EMT</kwd><kwd>phenotyping screening</kwd><kwd>mice</kwd><kwd>serotonin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001349</institution-id><institution>National Medical Research Council</institution></institution-wrap></funding-source><award-id>R-154000547511</award-id><principal-award-recipient><name><surname>Gong</surname><given-names>Zhiyuan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001459</institution-id><institution>Ministry of Education - Singapore</institution></institution-wrap></funding-source><award-id>R-154000A23112</award-id><principal-award-recipient><name><surname>Gong</surname><given-names>Zhiyuan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Zebrafish embryo screen utilizing conserved mechanisms between cancer metastasis and zebrafish gastrulation identifies the HTR2C inhibitor pizotifen as anti-metastasis drugs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Metastasis, a leading contributor to the morbidity of cancer patients, occurs through multiple steps: invasion, intravasation, extravasation, colonization, and metastatic tumor formation (<xref ref-type="bibr" rid="bib71">Nguyen et al., 2009</xref>; <xref ref-type="bibr" rid="bib115">Welch and Hurst, 2019</xref>; <xref ref-type="bibr" rid="bib9">Chaffer and Weinberg, 2011</xref>). The physical translocation of cancer cells is an initial step of metastasis and molecular mechanisms of it involve cell motility, the breakdown of local basement membrane, loss of cell polarity, acquisition of stem cell-like properties, and epithelial-to-mesenchymal transition (EMT) (<xref ref-type="bibr" rid="bib105">Tsai and Yang, 2013</xref>; <xref ref-type="bibr" rid="bib55">Lu and Kang, 2019</xref>). These cell-biological phenomena are also observed during vertebrate gastrulation in that evolutionarily conserved morphogenetic movements of epiboly, internalization, convergence, and extension progress (<xref ref-type="bibr" rid="bib92">Solnica-Krezel, 2005</xref>). In zebrafish, the first morphogenetic movement, epiboly, is initiated at approximately 4 hr post fertilization (hpf) to move cells from the animal pole to eventually engulf the entire yolk cell by 10 hpf (<xref ref-type="bibr" rid="bib46">Latimer and Jessen, 2010</xref>; <xref ref-type="bibr" rid="bib93">Solnica-Krezel, 2006</xref>). The embryonic cell movements are governed by the molecular mechanisms that are partially shared in metastatic cell dissemination.</p><p>At least 50 common genes were shown to be involved in both metastasis and gastrulation progression: Knockdown of these genes in <italic>Xenopus</italic> or zebrafish induced gastrulation defects; conversely, overexpression of these genes conferred metastatic potential on cancer cells and knockdown of these genes suppressed metastasis (<xref ref-type="bibr" rid="bib124">Yang and Weinberg, 2008</xref>; <xref ref-type="bibr" rid="bib15">Dongre and Weinberg, 2019</xref>; <xref ref-type="bibr" rid="bib102">Thiery et al., 2009</xref>; <xref ref-type="bibr" rid="bib73">Nieto et al., 2016</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). This evidence led us to hypothesize that small molecules that interrupt zebrafish gastrulation may suppress metastatic progression of human cancer cells.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>A list of the genes that are involved between gastrulation and metastasis progression.</title><p>A list of the 50 genes that play essential role in governing both metastasis and gastrulation progression. The gastrulation defects in <italic>Xenopus</italic> or zebrafish that are induced by knockdown of each of these genes were indicated. The molecular mechanism in metastasis that is inhibited by knockdown of each of the same genes was indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Genes</th><th align="left" valign="bottom">Gastrulation defects</th><th align="left" valign="bottom">Ref</th><th align="left" valign="bottom">Effects in metastasis</th><th align="left" valign="bottom">Ref</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>BMP</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib39">Kondo, 2007</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Katsuno et al., 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>WNT</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib100">Tada and Smith, 2000</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib109">Vincan and Barker, 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>FGF</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib122">Yang et al., 2002</xref></td><td align="left" valign="bottom">Invision</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib74">Nomura et al., 2008</xref></td></tr><tr><td align="left" valign="bottom">EGF</td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib94">Song et al., 2013</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib54">Lu et al., 2001</xref></td></tr><tr><td align="left" valign="bottom"><italic>PDGF</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib14">Damm and Winklbauer, 2011</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Jechlinger et al., 2006</xref></td></tr><tr><td align="left" valign="bottom"><italic>CXCL12</italic></td><td align="left" valign="bottom">Migration of endodermal cells</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib66">Mizoguchi et al., 2008</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib87">Shen et al., 2013</xref></td></tr><tr><td align="left" valign="bottom"><italic>CXCR4</italic></td><td align="left" valign="bottom">Migration of endodermal cells</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib66">Mizoguchi et al., 2008</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib87">Shen et al., 2013</xref></td></tr><tr><td align="left" valign="bottom"><italic>PIK3CA</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib67">Montero et al., 2003</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib110">Wander et al., 2013</xref></td></tr><tr><td align="left" valign="bottom"><italic>YES</italic></td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib103">Tsai et al., 2005</xref></td><td align="left" valign="bottom">Migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Barraclough et al., 2007</xref></td></tr><tr><td align="left" valign="bottom"><italic>FYN</italic></td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib86">Sharma et al., 2005</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib118">Yadav and Denning, 2011</xref></td></tr><tr><td align="left" valign="bottom"><italic>MAPK1</italic></td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib40">Krens et al., 2008</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib78">Radtke et al., 2013</xref></td></tr><tr><td align="left" valign="bottom">SHP2</td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Jopling et al., 2007</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib111">Wang et al., 2005</xref></td></tr><tr><td align="left" valign="bottom"><italic>SNAI1</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Ip and Gridley, 2002</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib4">Batlle et al., 2000</xref></td></tr><tr><td align="left" valign="bottom"><italic>SNAI2</italic></td><td align="left" valign="bottom">Mesoderm and neural crest formation</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib89">Shi et al., 2011</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib63">Medici et al., 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>TWIST1</italic></td><td align="left" valign="bottom">Mesoderm formation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Castanon and Baylies, 2002</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib123">Yang et al., 2004</xref></td></tr><tr><td align="left" valign="bottom"><italic>TBXT</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib100">Tada and Smith, 2000</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib18">Fernando et al., 2010</xref></td></tr><tr><td align="left" valign="bottom"><italic>ZEB1</italic></td><td align="left" valign="bottom">Epiboly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib107">Vannier et al., 2013</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib95">Spaderna et al., 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>GSC</italic></td><td align="left" valign="bottom">Mesodermal patterning</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib83">Sander et al., 2007</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Hartwell et al., 2006</xref></td></tr><tr><td align="left" valign="bottom"><italic>FOXC2</italic></td><td align="left" valign="bottom">Unclear, defects in gastrulation</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib117">Wilm et al., 2004</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib60">Mani et al., 2007</xref></td></tr><tr><td align="left" valign="bottom"><italic>STAT3</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib65">Miyagi et al., 2004</xref></td><td align="left" valign="bottom">Migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Abdulghani et al., 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>POU5F1</italic></td><td align="left" valign="bottom">Epiboly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Lachnit et al., 2008</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib13">Dai et al., 2013</xref></td></tr><tr><td align="left" valign="bottom"><italic>EZH2</italic></td><td align="left" valign="bottom">Unclear, defects in gastrulation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib75">O’Carroll et al., 2001</xref></td><td align="left" valign="bottom">Invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib79">Ren et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>EHMT2</italic></td><td align="left" valign="bottom">Defects in neurogenesis</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib49">Lin et al., 2005</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Chen et al., 2010</xref></td></tr><tr><td align="left" valign="bottom"><italic>BMI1</italic></td><td align="left" valign="bottom">Defects in skeleton formation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib106">van der Lugt et al., 1994</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Guo et al., 2011</xref></td></tr><tr><td align="left" valign="bottom"><italic>RHOA</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib128">Zhu et al., 2006</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib125">Yoshioka et al., 1999</xref></td></tr><tr><td align="left" valign="bottom"><italic>CDC42</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Choi and Han, 2002</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib80">Reymond et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>RAC1</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib23">Habas et al., 2003</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib108">Vega and Ridley, 2008</xref></td></tr><tr><td align="left" valign="bottom"><italic>ROCK2</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib61">Marlow et al., 2002</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib32">Itoh et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">PAR1</td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Kusakabe and Nishida, 2004</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib88">Shi et al., 2004</xref></td></tr><tr><td align="left" valign="bottom">PRKCI</td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Kusakabe and Nishida, 2004</xref></td><td align="left" valign="bottom">EMT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib20">Gunaratne et al., 2013</xref></td></tr><tr><td align="left" valign="bottom"><italic>CAP1</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib85">Seifert et al., 2009</xref></td><td align="left" valign="bottom">Migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib121">Yamazaki et al., 2009</xref></td></tr><tr><td align="left" valign="bottom"><italic>EZR</italic></td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib51">Link et al., 2006</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib36">Khanna et al., 2004</xref></td></tr><tr><td align="left" valign="bottom">EPCAM</td><td align="left" valign="bottom">Epiboly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib91">Slanchev et al., 2009</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib72">Ni et al., 2012</xref></td></tr><tr><td align="left" valign="bottom">ITGB1/ ITA5</td><td align="left" valign="bottom">Mesodermal migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib90">Skalski et al., 1998</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Felding-Habermann, 2003</xref></td></tr><tr><td align="left" valign="bottom"><italic>FN1</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Marsden and DeSimone, 2003</xref></td><td align="left" valign="bottom">Invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib59">Malik et al., 2010</xref></td></tr><tr><td align="left" valign="bottom">HAS2</td><td align="left" valign="bottom">Dorsal migration of lateral cells</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Bakkers et al., 2004</xref></td><td align="left" valign="bottom">Invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib37">Kim et al., 2004</xref></td></tr><tr><td align="left" valign="bottom"><italic>MMP14</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib12">Coyle et al., 2008</xref></td><td align="left" valign="bottom">Invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib77">Perentes et al., 2011</xref></td></tr><tr><td align="left" valign="bottom"><italic>COX1</italic></td><td align="left" valign="bottom">Epiboly</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib8">Cha et al., 2006</xref></td><td align="left" valign="bottom">Invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Kundu and Fulton, 2002</xref></td></tr><tr><td align="left" valign="bottom"><italic>PTGES</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib96">Speirs et al., 2010</xref></td><td align="left" valign="bottom">Invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib112">Wang and Dubois, 2006</xref></td></tr><tr><td align="left" valign="bottom"><italic>SLC39A6</italic></td><td align="left" valign="bottom">Anterior migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib120">Yamashita et al., 2004</xref></td><td align="left" valign="bottom">EMT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib56">Lue et al., 2011</xref></td></tr><tr><td align="left" valign="bottom">GNA12 /13</td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib49">Lin et al., 2005</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib119">Yagi et al., 2011</xref></td></tr><tr><td align="left" valign="bottom"><italic>OGT</italic></td><td align="left" valign="bottom">Epiboly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib113">Webster et al., 2009</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib57">Lynch et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>CCN1</italic></td><td align="left" valign="bottom">Cell movement</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Latinkic et al., 2003</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib50">Lin et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>TRPM7</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib52">Liu et al., 2011</xref></td><td align="left" valign="bottom">Migration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Middelbeek et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>MAPKAPK2</italic></td><td align="left" valign="bottom">Epiboly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib26">Holloway et al., 2009</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib42">Kumar et al., 2010</xref></td></tr><tr><td align="left" valign="bottom"><italic>B4GALT1</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Machingo et al., 2006</xref></td><td align="left" valign="bottom">Invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib127">Zhu et al., 2005</xref></td></tr><tr><td align="left" valign="bottom"><italic>IER2</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib27">Hong et al., 2011</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib70">Neeb et al., 2012</xref></td></tr><tr><td align="left" valign="bottom">TIP1</td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib5">Besser et al., 2007</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib24">Han et al., 2012</xref></td></tr><tr><td align="left" valign="bottom"><italic>PAK5</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib16">Faure et al., 2005</xref></td><td align="left" valign="bottom">Migration</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib19">Gong et al., 2009</xref></td></tr><tr><td align="left" valign="bottom"><italic>MARCKS</italic></td><td align="left" valign="bottom">Convergence and extension</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib30">Iioka et al., 2004</xref></td><td align="left" valign="bottom">Migration and invasion</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib81">Rombouts et al., 2013</xref></td></tr></tbody></table></table-wrap><p>Here, we report a unique screening concept based on the hypothesis. Pizotifen, an antagonist for HTR2C, was identified from the screen as a ‘hit’ that interrupted zebrafish gastrulation. A mouse model of metastasis confirmed pharmacological and genetic inhibition of HTR2C suppressed metastatic progression. Moreover, HTR2C induced EMT and promoted metastatic dissemination of non-metastatic cancer cells in a zebrafish xenotransplantation model. These results demonstrated that this concept could offer a novel high-throughput platform for discovery of anti-metastasis drugs and can be converted to a chemical genetic screening platform.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Small molecules interrupting epiboly of zebrafish have a potential to suppress metastatic progression of human cancer cells</title><p>Before performing a screening assay, we validated a core of our concept through comparing the genes expressed in zebrafish gastrulation with the genes which expressed in EMT-mediated metastasis. Gene set enrichment analysis (GSEA) demonstrated that 50%-epiboly, shield, and 75%-epiboly stage of zebrafish embryos expressed the genes which promote EMT-mediated metastasis: EMT induction, TGF-β signaling, wnt/β-catenin signaling, Notch signaling (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>We further conducted preliminary experiments to test the hypothesis. First, we examined whether hindering the molecular function of reported genes, whose knockdown induced gastrulation defects in zebrafish, might suppress cell motility and invasion of cancer cells. We chose protein arginine methyltransferase 1 (PRMT1) and cytochrome P450 family 11 (CYP11A1), both of whose knockdown induced gastrulation defects in zebrafish but whose involvement in metastatic progression is unclear (<xref ref-type="bibr" rid="bib104">Tsai et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Hsu et al., 2006</xref>). Elevated expression of PRMT1 and CYP11A1 was observed in highly metastatic human breast cancer cell lines and knockdown of these genes through RNA interference suppressed the motility and invasion of MDA-MB-231 cells without affecting their viability (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A-C</xref>).</p><p>Next, we conducted an inverse examination of whether chemicals which were reported to suppress metastatic dissemination of cancer cells could interrupt epiboly progression of zebrafish embryos. Niclosamide and vinpocetine are reported to suppress metastatic progression (<xref ref-type="bibr" rid="bib114">Weinbach and Garbus, 1969</xref>; <xref ref-type="bibr" rid="bib82">Sack et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Huang et al., 2012</xref>; <xref ref-type="bibr" rid="bib99">Szilágyi et al., 2005</xref>). Either niclosamide- or vinpocetine-treated zebrafish embryos showed complete arrest at very early stages or severe delay in epiboly progression, respectively (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>).</p><p>These results suggest that epiboly could serve as a marker for this screening assay and epiboly-interrupting drugs that are identified through this screening could have the potential to suppress metastatic progression of human cancer cells.</p></sec><sec id="s2-2"><title>132 FDA-approved drugs induced delayed in epiboly of zebrafish embryos</title><p>We screened 1280 FDA, EMA, or other agencies-approved drugs (Prestwick, Inc) in our zebrafish assay. The screening showed that 0.9% (12/1280) of the drugs, including antimycin A and tolcapone, induced severe or complete arrest of embryonic cell movement when embryos were treated with 10 μM. 5.2% (66/1280) of the drugs, such as dicumarol, racecadotril, pizotifen, and S(-)eticlopride hydrochloride, induced either delayed epiboly or interrupted epiboly of the embryos. 93.3% (1194/1280) of drugs have no effect on epiboly progression of the embryos. 0.6% (8/1280) of drugs induced toxic lethality. Epiboly progression was affected more severely when embryos were treated with 50 μM; 1.7% (22/1280) of the drugs induced severe or complete arrest of it. 8.6% (110/1280) of the drugs induced either delayed epiboly or interrupt epiboly of the embryos. 4.3% (55/1280) of drugs induced a toxic lethality (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). Among the epiboly-interrupting drugs, several drugs have already been reported to inhibit metastasis-related molecular mechanisms: adrenosterone or zardaverine, which target HSD11β1 or PDE3 and -4, respectively, are reported to inhibit EMT (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Kolosionek et al., 2009</xref>); racecadotril, which targets enkephalinase, is reported to confer metastatic potential on colon cancer cell (<xref ref-type="bibr" rid="bib84">Sasaki et al., 2014</xref>); and disulfiram, which targets ALDH (aldehyde dehydrogenase), is reported to confer stem-like properties on metastatic cancer cells (<xref ref-type="bibr" rid="bib53">Liu et al., 2013</xref>). This evidence suggests that epiboly-interrupting drugs have the potential for suppressing metastasis of human cancer cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>A chemical screen for identification of epiboly-interrupting drugs.</title><p>(<bold>A</bold>) Cumulative results of the chemical screen in which each drug was used at either 10 µM (left) or 50 µM (right) concentrations. 1280 FDA, EMA, or other agencies-approved drugs were subjected to this screening. Positive ‘hit’ drugs were those that interrupted epiboly progression. (<bold>B</bold>) Representative samples of the embryos that were treated with indicated drugs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig1-v4.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Gene expression profiles obtained from zebrafish embryos at either 50%-epiboly (top left), shield (top right), or 75%-epiboly stage (bottom left) were analyzed based on the hallmark gene sets derived from the Molecular Signatures Database (MSigDB) (<xref ref-type="bibr" rid="bib48">Liberzon et al., 2015</xref>).</title><p>The zebrafish transcriptomic data was sourced from <xref ref-type="bibr" rid="bib116">White et al., 2017</xref> eLife (<xref ref-type="bibr" rid="bib97">Subramanian et al., 2005</xref>). Gene sets that were significantly enriched (FDR &lt; 0.25) were presented with the normalized enrichment score (NES) and nominal p value. Source data files for analysis of either gene expression and enriched pathways are uploaded as gene set enrichment analysis (GSEA) <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref> and <xref ref-type="supplementary-material" rid="sdata2">2</xref>, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig1-figsupp1-v4.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Epiboly could serve as a marker for this screening.</title><p>(<bold>A</bold>) Western blot analysis of protein arginine methyltransferase 1 (PRMT1) (upper left) and cytochrome P450 family 11 (CYP11A1) (middle left) protein levels in non-metastatic human cancer cell line (MCF7) and highly metastatic human cancer cell lines (MDA-MB-231, MDA-MB-435, MIA-PaCa2, PC9, HCCLM3, PC3, and SW620); β-actin loading control is shown (bottom left). Preliminary experiments confirmed that epiboly could serve as a marker for this screening assay. Quantification analyses of western blotting bands. The analyses were performed by ImageJ. Signal strength of bands of PRMT1 (Top right) and CYP11A1 (bottom right) was normalized by that of β-actin. (<bold>B</bold>) Knockdown of PRMT1 or CYP11A1 in MDA-MB-231 cells. MBA-MB-231 cells were transfected with a control short hairpin RNA (shRNA) targeting LacZ, and one of four independent shRNAs targeting PRMT1 (clones #1 to #4), or one of two independent shRNAs targeting CYP11A1 (clones #1 to #4). Reduced PRMT1 and CYP11A1 expression, determined by western blot, in sub-cell lines of MDA-MB-231 cells expressing PRMT1 shRNA (clones #3 and #4) or CYP11A1 (clones #2 and #4), compared with controls (parental cell line MDA-MB-231 and control shRNA cells); β-actin levels shown as a loading control. Quantification analyses of western blotting bands. The analyses were performed by ImageJ. Signal strength of bands of PRMT1 (top right) and CYP11A1 (bottom right) was normalized by that of β-actin. (<bold>C</bold>) Effect of shRNAs targeting either PRMT1 or CYP11A1 on cell motility and invasion of MBA-MB-231 cells. Parental MDA-MB-231 cells and four sub-cell lines of MDA-MB-231 cells that were transfected with either shRNA targeting either LacZ, two independent shRNAs targeting PRMT1 (clones #3 and #4) or two independent shRNAs targeting CYP11A1 (clones #2 and #4) were subjected to Boyden chamber assays. (<bold>D</bold>) Zebrafish embryos treated with either vehicle (DMSO), 10 μM niclosamide, or 50 µM vinpocetine. Approximately 20 embryos were treated with either DMSO as a vehicle control, niclosamide, or vinpocetine. The treatment was started at 4 hours post fertilization (hpf) when all of embryos reached sphere stage and ended at 9 hpf when control embryos reached 80–90% epiboly stage. Each experiment was performed at least twice. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig1-figsupp2-v4.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>A list of the drugs that interfere with epiboly progression in zebrafish.</title><p>Related to <xref ref-type="fig" rid="fig1">Figure 1</xref>. A list of positive ‘hit’ drugs that interfered with epiboly progression. Gastrulation defects or status of each of the zebrafish embryos that were treated with either 10 or 50 μM concentrations are indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Chemical name</th><th align="left" valign="bottom">Chemical formula</th><th align="left" valign="bottom">Effect of 10 µM</th><th align="left" valign="bottom">Effect of 50 µM</th></tr></thead><tbody><tr><td align="left" valign="bottom">Acitretin</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>26</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Adrenosterone</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>24</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Albendazole</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S</td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Alfadolone acetate</td><td align="left" valign="bottom">C<sub>23</sub>H<sub>34</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Alfaxalone</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>32</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Alprostadil</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>34</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Altrenogest</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>26</sub>O<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ampiroxicam</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>7</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Anethole-trithione</td><td align="left" valign="bottom">C<sub>10</sub>H<sub>8O</sub>S<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Antimycin A</td><td align="left" valign="bottom">C<sub>28</sub>H<sub>40</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Avobenzone</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>22</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Benzoxiquine</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>11</sub>NO<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Bosentan</td><td align="left" valign="bottom">C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>6</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Butoconazole nitrate</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>18</sub>C<sub>l3</sub>N<sub>3</sub>O<sub>3</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Camptothecine (S,+)</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Carbenoxolone disodium salt</td><td align="left" valign="bottom">C<sub>34</sub>H<sub>48</sub>Na<sub>2</sub>O<sub>7</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Carmofur</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Carprofen</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>12</sub>ClNO<sub>2</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Cefdinir</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>13</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Celecoxib</td><td align="left" valign="bottom">C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Chlorambucil</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>19</sub>C<sub>l2</sub>NO<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Chlorhexidine</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>30</sub>C<sub>l2</sub>N<sub>10</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Ciclopirox ethanolamine</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Cinoxacin</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>10</sub>N<sub>2</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Clofibrate</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>15</sub>ClO<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Clopidogrel</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>16</sub>ClNO<sub>2</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Clorgyline hydrochloride</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>16</sub>Cl<sub>3</sub>NO</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Colchicine</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>25</sub>NO<sub>6</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Deptropine citrate</td><td align="left" valign="bottom">C<sub>29</sub>H<sub>35</sub>NO<sub>8</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Desipramine hydrochloride</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>23</sub>ClN<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Diclofenac sodium</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Dicumarol</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>12</sub>O<sub>6</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Diethylstilbestrol</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>20</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Dimaprit dihydrochloride</td><td align="left" valign="bottom">C<sub>6</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>S</td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Disulfiram</td><td align="left" valign="bottom">C<sub>10</sub>H<sub>20</sub>N<sub>2</sub>S<sub>4</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Dopamine hydrochloride</td><td align="left" valign="bottom">C<sub>8</sub>H<sub>12</sub>ClNO<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Eburnamonine (-)</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ethaverine hydrochloride</td><td align="left" valign="bottom">C<sub>24</sub>H<sub>30</sub>ClNO<sub>4</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ethinylestradiol</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>24</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Ethopropazine hydrochloride</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>25</sub>ClN<sub>2</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ethoxyquin</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>19</sub>NO</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Exemestane</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>24</sub>O<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ezetimibe</td><td align="left" valign="bottom">C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>NO<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Fenbendazole</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Fenoprofen calcium salt dihydrate</td><td align="left" valign="bottom">C<sub>30</sub>H<sub>30</sub>CaO<sub>8</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Fentiazac</td><td align="left" valign="bottom">C<sub>17</sub>H<sub>12</sub>ClNO<sub>2</sub>S</td><td align="left" valign="bottom">Toxic lethal</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Floxuridine</td><td align="left" valign="bottom">C<sub>9</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Flunixin meglumine</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>28</sub>F<sub>3</sub>N<sub>3</sub>O<sub>7</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Flutamide</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Fluticasone propionate</td><td align="left" valign="bottom">C<sub>25</sub>H<sub>31</sub>F<sub>3</sub>O<sub>5</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Furosemide</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>5</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Gatifloxacin</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>4</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Gemcitabine</td><td align="left" valign="bottom">C<sub>9</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Gemfibrozil</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>22</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Gestrinone</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>24</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Haloprogin</td><td align="left" valign="bottom">C<sub>9</sub>H<sub>4</sub>Cl<sub>3</sub>IO</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Hexachlorophene</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>6</sub>Cl<sub>6</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Hexestrol</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>22</sub>O<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ibudilast</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Idazoxan hydrochloride</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Idazoxan hydrochloride</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Idebenone</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>30</sub>O<sub>5</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Indomethacin</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>16</sub>ClNO<sub>4</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ipriflavone</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>16</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Isotretinoin</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>28</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Isradipine</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Lansoprazole</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S</td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Latanoprost</td><td align="left" valign="bottom">C<sub>26</sub>H<sub>40</sub>O<sub>5</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Leflunomide</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Letrozole</td><td align="left" valign="bottom">C<sub>17</sub>H<sub>11</sub>N<sub>5</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Lithocholic acid</td><td align="left" valign="bottom">C<sub>24</sub>H<sub>40</sub>O<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Lodoxamide</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>6</sub>ClN<sub>3</sub>O<sub>6</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Lofepramine</td><td align="left" valign="bottom">C<sub>26</sub>H<sub>27</sub>ClN<sub>2</sub>O</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Loratadine</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Loxapine succinate</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Mebendazole</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Mebendazole</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Meloxicam</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Methiazole</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Mevastatin</td><td align="left" valign="bottom">C<sub>23</sub>H<sub>34</sub>O<sub>5</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">MK 801 hydrogen maleate</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>19</sub>NO<sub>4</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Nabumetone</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>16</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Naftopidil dihydrochloride</td><td align="left" valign="bottom">C<sub>24</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Nandrolone</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>26</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Naproxen sodium salt</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>13</sub>NaO<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Niclosamide</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Nifekalant</td><td align="left" valign="bottom">C<sub>19</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Niflumic acid</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Nimesulide</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>5</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Nisoldipine</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Nitazoxanide</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S</td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Norethindrone</td><td align="left" valign="bottom">C<sub>20</sub>H<sub>26</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Norgestimate</td><td align="left" valign="bottom">C<sub>23</sub>H<sub>31</sub>NO<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Oxfendazol</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>S</td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Oxibendazol</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Oxymetholone</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>32</sub>O<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Parbendazole</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Parthenolide</td><td align="left" valign="bottom">C<sub>15</sub>H<sub>20</sub>O<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Penciclovir</td><td align="left" valign="bottom">C<sub>10</sub>H<sub>15</sub>N<sub>5</sub>O<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Pentobarbital</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Phenazopyridine hydrochloride</td><td align="left" valign="bottom">C<sub>11</sub>H<sub>12</sub>ClN<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Phenothiazine</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>9</sub>NS</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Phenoxybenzamine hydrochloride</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>23</sub>Cl<sub>2</sub>NO</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Pizotifen malate</td><td align="left" valign="bottom">C<sub>23</sub>H<sub>27</sub>NO<sub>5</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Pramoxine hydrochloride</td><td align="left" valign="bottom">C<sub>17</sub>H<sub>28</sub>ClNO<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Prilocaine hydrochloride</td><td align="left" valign="bottom">C<sub>13</sub>H<sub>21</sub>ClN<sub>2</sub>O</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Primidone</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Racecadotril</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>23</sub>NO<sub>4</sub>S</td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Riluzole hydrochloride</td><td align="left" valign="bottom">C<sub>8</sub>H<sub>6</sub>ClF<sub>3</sub>N<sub>2</sub>OS</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Ritonavir</td><td align="left" valign="bottom">C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">S(-)Eticlopride hydrochloride</td><td align="left" valign="bottom">C<sub>17</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Salmeterol</td><td align="left" valign="bottom">C<sub>25</sub>H<sub>37</sub>NO<sub>4</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Streptomycin sulfate</td><td align="left" valign="bottom">C<sub>42</sub>H<sub>84</sub>N<sub>14</sub>O<sub>36</sub>S<sub>3</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Sulconazole nitrate</td><td align="left" valign="bottom">C<sub>18</sub>H<sub>16</sub>C<sub>l3</sub>N<sub>3</sub>O<sub>3</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Tegafur</td><td align="left" valign="bottom">C<sub>8</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Telmisartan</td><td align="left" valign="bottom">C<sub>33</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Tenatoprazole</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Terbinafine</td><td align="left" valign="bottom">C<sub>21</sub>H<sub>25</sub>N</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Thimerosal</td><td align="left" valign="bottom">C<sub>9</sub>H<sub>9</sub>HgNaO<sub>2</sub>S</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Thiorphan</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>15</sub>NO<sub>3</sub>S</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Tolcapone</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>11</sub>NO<sub>5</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Topotecan</td><td align="left" valign="bottom">C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Tracazolate hydrochloride</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>2</sub></td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Tribenoside</td><td align="left" valign="bottom">C<sub>29</sub>H<sub>34</sub>O<sub>6</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Triclabendazole</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>9</sub>Cl<sub>3</sub>N<sub>2</sub>OS</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Triclosan</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>7</sub>Cl<sub>3</sub>O<sub>2</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Severe delayed</td></tr><tr><td align="left" valign="bottom">Trioxsalen</td><td align="left" valign="bottom">C<sub>14</sub>H<sub>12</sub>O<sub>3</sub></td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Troglitazone</td><td align="left" valign="bottom">C<sub>24</sub>H<sub>27</sub>NO<sub>5</sub>S</td><td align="left" valign="bottom">Severe delayed</td><td align="left" valign="bottom">Toxic lethal</td></tr><tr><td align="left" valign="bottom">Valproic acid</td><td align="left" valign="bottom">C<sub>8</sub>H<sub>16</sub>O<sub>2</sub></td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Voriconazole</td><td align="left" valign="bottom">C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O</td><td align="left" valign="bottom">Non-effect</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Zardaverine</td><td align="left" valign="bottom">C<sub>12</sub>H<sub>10</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub></td><td align="left" valign="bottom">Slightly delayed</td><td align="left" valign="bottom">Delayed</td></tr><tr><td align="left" valign="bottom">Zuclopenthixol dihydrochloride</td><td align="left" valign="bottom">C<sub>22</sub>H<sub>27</sub>Cl<sub>3</sub>N<sub>2</sub>OS</td><td align="left" valign="bottom">Delayed</td><td align="left" valign="bottom">Delayed</td></tr></tbody></table></table-wrap></sec><sec id="s2-3"><title>Identified drugs suppressed cell motility and invasion of human cancer cells</title><p>It has been reported that zebrafish have orthologues to 86% of 1318 human drug targets (<xref ref-type="bibr" rid="bib21">Gunnarsson et al., 2008</xref>). However, it was not known whether the epiboly-interrupting drugs could suppress metastatic dissemination of human cancer cells. To test this, we subjected the 78 epiboly-interrupting drugs that showed a suppressor effect on epiboly progression at a 10 μM concentration to in vitro experiments using a human cancer cell line. The experiments examined whether the drugs could suppress cell motility and invasion of MDA-MB-231 cells through a Boyden chamber. Before conducting the experiment, we investigated whether these drugs might affect viability of MDA-MB-231 cells using an MTT assay. Out of the 78 drugs, 16 of them strongly affected cell viability at concentrations less than 1 μM and were not used in the cell motility experiments. The remaining 62 drugs were assayed in Boyden chamber motility experiments. Out of the 62 drugs, 20 of the drugs inhibited cell motility and invasion of MDA-MB-231 cells without affecting cell viability. Among the 20 drugs, hexachlorophene and nitazoxanide were removed since the primary targets of the drugs, D-lactate dehydrogenase and pyruvate ferredoxin oxidoreductase, are not expressed in mammalian cells. With the exception of ipriflavone, whose target is still unclear, the known primary targets of the remaining 17 drugs are reported to be expressed by mammalian cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="table" rid="table3">Table 3</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Pizotifen, one of epiboly-interrupting drugs, suppressed metastatic dissemination of human cancer cells lines in vivo and vitro.</title><p>(<bold>A</bold>) Effect of the epiboly-interrupting drugs on cell motility and invasion of MBA-MB-231 cells. MBA-MB-231 cells were treated with vehicle or each of the epiboly-interrupting drugs and then subjected to Boyden chamber assays. Fetal bovine serum (1% v/v) was used as the chemoattractant in both assays. Each experiment was performed at least twice. (<bold>B</bold>) Western blot analysis of HTR2C levels (top) in a non-metastatic human cancer cell line, MCF7 (breast) and highly metastatic human cancer cell lines, MDA-MB-231 (breast), MDA-MB-435 (melanoma), PC9 (lung), MIA-PaCa2 (pancreas), PC3 (prostate), and SW620 (colon); GAPDH loading control is shown (bottom). (<bold>C</bold>) Effect of pizotifen on cell motility and invasion of MBA-MB-231, MDA-MB-435, and PC9 cells. Either vehicle or pizotifen treated the cells were subjected to Boyden chamber assays. Fetal bovine serum (1% v/v) was used as the chemoattractant in both assays. Each experiment was performed at least twice. (<bold>D</bold>) and (<bold>E</bold>) Representative images of dissemination of 231R, shLacZ 231R or shHTR2C 231R cells in zebrafish xenotransplantation model. The fish larvae that were inoculated with 231R cells were treated with either vehicle (top left) or the drug (lower left) (<bold>D</bold>). The fish larvae that were inoculated with either shLacZ 231R or shHTR2C 231R cells (lower left) (<bold>E</bold>). White arrows head indicate disseminated 231R cells. The images were shown in 4× magnification. Scale bar, 100 µm. The mean frequencies of the fish showing head, trunk, or end-tail dissemination were counted (graph on right). Each value is indicated as the mean ± SEM of two independent experiments. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig2-v4.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Blocking Dopamine receptor D2 with S(-) Eticlopride hydrochloride suppressed cell motility and invasion of highly metastatic human cancer cells in a dose-dependent manner.</title><p>(<bold>A</bold>) Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. The analyses were performed by ImageJ. Signal strength of bands of HTR2C (left) and DRD2 (right) was normalized by that of GAPDH. (<bold>B</bold>) Western blot analysis of DRD2 levels in non-metastatic human cancer cell line, MCF7 (breast) and highly metastatic human cancer cell lines, MDA-MB-231 (breast), MDA-MB-435 (melanoma), MIA-PaCa2 (pancreas), PC3 (prostate), and SW620 (colon); GAPDH loading control is shown (bottom). GAPDH control was obtained in the same experiment from <xref ref-type="fig" rid="fig2">Figure 2B</xref>. (<bold>C</bold>) Effect of S(-)eticlopride hydrochloride on cell motility and invasion of MBA-MB-231, MDA-MB-435, and PC9 cells. Either vehicle- or pizotifen-treated cells were subjected to Boyden chamber assays. Fetal bovine serum (1% v/v) was used as the chemoattractant in both assays. Each experiment was performed at least twice. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig2-figsupp1-v4.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Pizotifen suppressed metastatic dissemination of MDA-MB-231 and MIA-PaCa2 cells in a zebrafish xenotransplantation model.</title><p>(<bold>A</bold>) Representative images of dissemination of 231R cells in zebrafish xenotransplantation model. The fish larvae that were inoculated with 231R cells were treated with either vehicle (top left, bottom left) or pizotifen (top right, bottom right). (<bold>B</bold>) Representative images of dissemination of MIA-PaCa2 cells in zebrafish xenotransplantation model. The fish were inoculated with MIA-PaCa2 cells, and treated with either vehicle (top left) or drug (lower left). White arrow heads indicate disseminated MIA-PaCa2 cells. The images were shown in 4× magnification. Scale bar, 100 μm. The mean frequencies of the fish showing head, trunk, or end-tail dissemination were tabulated (right). Each value is indicated as the mean ± SEM of two independent experiments. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig2-figsupp2-v4.tif"/></fig></fig-group><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Primary targets of the identified drugs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">The identified drugs</th><th align="left" valign="top">Primary targets of the identified drugs</th></tr></thead><tbody><tr><td align="left" valign="top">Hexachlorophene</td><td align="left" valign="top">D-Lactate dehydrogenase (D-LDH), not expressed in mammalian cells</td></tr><tr><td align="left" valign="top">Troglitazone</td><td align="left" valign="top">Agonist for peroxisome proliferator-activated receptor α and γ (PPARα and -γ)</td></tr><tr><td align="left" valign="top">Pizotifen malate</td><td align="left" valign="top">5-Hydroxytryptamine receptor 2C (HTR2C)</td></tr><tr><td align="left" valign="top">Salmeterol</td><td align="left" valign="top">Adrenergic receptor beta 2 (ADRB2)</td></tr><tr><td align="left" valign="top">Nitazoxanide</td><td align="left" valign="top">Pyruvate ferredoxin oxidoreductase (PFOR), not expressed in mammalian cells</td></tr><tr><td align="left" valign="top">Valproic acid</td><td align="left" valign="top">Histone deacetylases (HDACs)</td></tr><tr><td align="left" valign="top">Dicumarol</td><td align="left" valign="top">NAD(P)H dehydrogenase quinone 1 (NQO1)</td></tr><tr><td align="left" valign="top">Loxapine succinate</td><td align="left" valign="top">Dopamine receptor D2 and D4 (DRD2 and DRD4)</td></tr><tr><td align="left" valign="top">Adrenosterone</td><td align="left" valign="top">Hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1)</td></tr><tr><td align="left" valign="top">Riluzole hydrochloride</td><td align="left" valign="top">Glutamate R and<break/>voltage-dependent Na+ channel</td></tr><tr><td align="left" valign="top">Naftopidil dihydrochloride</td><td align="left" valign="top">5-Hydroxytryptamine receptor 1A (HTR1A) and<break/>α1-adrenergic receptor (AR)</td></tr><tr><td align="left" valign="top">S(-)Eticlopride hydrochloride</td><td align="left" valign="top">Dopamine receptor D2 (DRD2)</td></tr><tr><td align="left" valign="top">Racecadotril</td><td align="left" valign="top">Membrane metallo-endopeptidase (MME)</td></tr><tr><td align="left" valign="top">Ipriflavone</td><td align="left" valign="top">Unknown</td></tr><tr><td align="left" valign="top">Flurbiprofen</td><td align="left" valign="top">Cyclooxygenase 1 and 2 (Cox1 and -2)</td></tr><tr><td align="left" valign="top">Zardaverine</td><td align="left" valign="top">Phosphodiesterase III/IV (PDE3/4)</td></tr><tr><td align="left" valign="top">Leflunomide</td><td align="left" valign="top">Dihydroorotate dehydrogenase (DHODH)</td></tr><tr><td align="left" valign="top">Olmesartan</td><td align="left" valign="top">Angiotensin II receptor alpha</td></tr><tr><td align="left" valign="top">Disulfiram</td><td align="left" valign="top">Aldehyde dehydrogenase (ALDH)<break/>Dopamine β-hydroxylase (DBH)</td></tr><tr><td align="left" valign="top">Zuclopenthixol dihydrochloride</td><td align="left" valign="top">Dopamine receptors D1 and D2 (DRD1 and -2)</td></tr></tbody></table></table-wrap><p>We confirmed that highly metastatic human cancer cell lines expressed target genes through western blotting analyses. Among the genes, serotonin receptor 2C (HTR2C), which is a primary target of pizotifen, was highly expressed in only metastatic cell lines (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Clinical data also shows that that HTR2C expression is correlated with tumor stage of breast cancer patients and is higher in metastatic and Her2/neu-overexpressing tumors (<xref ref-type="bibr" rid="bib76">Pai et al., 2009</xref>). Pizotifen suppressed cell motility and invasion of several highly metastatic human cancer cell lines in a dose-dependent manner (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Similarly, dopamine receptor D2 (DRD2), which is a primary target of S(-)eticlopride hydrochloride, was highly expressed in only metastatic cell lines, and the drug suppressed cell motility and invasion of these cells in a dose-dependent manner (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A-C</xref>).</p><p>These results indicate that a number of the epiboly-interrupting drugs also have suppressor effects on cell motility and invasion of highly metastatic human cancer cells.</p></sec><sec id="s2-4"><title>Pizotifen suppressed metastatic dissemination of human cancer cells in a zebrafish xenotransplantation model</title><p>While a number of the epiboly-interrupting drugs suppressed cell motility and invasion of human cell lines in vitro, it was still unclear whether the drugs could suppress metastatic dissemination of cancer cells in vivo. Therefore, we examined whether the identified drugs could suppress metastatic dissemination of these human cancer cells in a zebrafish xenotransplantation model. Pizotifen was selected to test since HTR2C was overexpressed only in highly metastatic cell lines supporting the hypothesis that it could be a novel target for blocking metastatic dissemination of cancer cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Red fluorescent protein (RFP)-labelled MDA-MB-231 (231R) cells were injected into the duct of Cuvier of <italic>Tg (kdrl:eGFP</italic>) zebrafish at 2 dpf and then maintained in the presence of either vehicle or pizotifen. Twenty-four hours post injection, the numbers of fish showing metastatic dissemination of 231R cells were measured via fluorescence microscopy. In this model, the dissemination patterns were generally divided into three categories: (i) head dissemination, in which disseminated 231R cells exist in the vessel of the head part; (ii) trunk dissemination, in which the cells were observed in the vessel dilating from the trunk to the tail; (iii) end-tail dissemination, in which the cells were observed in the vessel of the end-tail part (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>).</p><p>Three independent experiments revealed that the frequencies of fish in the drug-treated group showing head, trunk, or end-tail dissemination significantly decreased to 55.3% ± 7.5%, 28.5 ± 5.0%, or 43.5% ± 19.1% when compared with those in the vehicle-treated group; 95.8% ± 5.8%, 47.1 ± 7.7%, or 82.6% ± 12.7%. Conversely, the frequency of the fish in the drug-treated group not showing any dissemination significantly increased to 45.4% ± 0.5% when compared with those in the vehicle-treated group; 2.0% ± 2.9% (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> and <xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Effects of pharmacological inhibition of HTR2C on metastatic dissemination of MDA-MB-231 cells in zebrafish xenografted models.</title><p>Related to <xref ref-type="fig" rid="fig2">Figure 2D</xref>. The numbers and frequencies of the fish showing the dissemination patterns in vehicle- or pizotifen-treated group were indicated. The fish showed both patterns of dissemination were redundantly counted in this analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">Experiment_#1</th><th align="left" valign="bottom">Experiment_#2</th><th align="left" valign="bottom">Experiment_#3</th><th align="left" valign="bottom">Average of experiments</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4"> Drug: Vehicle<break/> Cell: MDA-MB-231</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">0% n1 = 0/17</td><td align="left" valign="bottom">0% n2 = 0/12</td><td align="left" valign="bottom">6.66% n3 = 1/15</td><td align="left" valign="bottom">2.22% ± 3.84%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">58.82% n1 = 10/17</td><td align="left" valign="bottom">91.66% n2 = 11/12</td><td align="left" valign="bottom">6.66% n3 = 1/15</td><td align="left" valign="bottom">72.38% ± 17.15%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">52.94% n1 = 9/17</td><td align="left" valign="bottom">8.33% n2 = 1/12</td><td align="left" valign="bottom">20% n3 = 2/15</td><td align="left" valign="bottom">27.09% ± 23.13%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">100% n1 = 17/17</td><td align="left" valign="bottom">100% n2 = 12/12</td><td align="left" valign="bottom">86.66% n3 = 13/15</td><td align="left" valign="bottom">95.55% ± 7.69%</td></tr><tr><td align="left" valign="bottom" rowspan="4"> Drug: Pizotifen<break/> Cell: MDA-MB-231</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">55% n1 = 11/20</td><td align="left" valign="bottom">31.57% n2 = 6/19</td><td align="left" valign="bottom">45.45 % n3 = 10/22</td><td align="left" valign="bottom">44.01% ± 11.77%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">5% n1 = 1/20</td><td align="left" valign="bottom">31.57% n2 = 6/19</td><td align="left" valign="bottom">18.18% n3 = 4/22</td><td align="left" valign="bottom">18.25% ± 13.28%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">5% n1 = 1/20</td><td align="left" valign="bottom">10.52% n2 = 2/19</td><td align="left" valign="bottom">4.45% n3 = 1/22</td><td align="left" valign="bottom">6.69% ± 3.32%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">45% n1 = 9/20</td><td align="left" valign="bottom">57.89% n2 = 11/19</td><td align="left" valign="bottom">50% n3 = 11/22</td><td align="left" valign="bottom">50.96% ± 6.50%</td></tr></tbody></table></table-wrap><p>Similar effects were observed in another xenograft experiments using an RFP-labelled human pancreatic cancer cell line, MIA-PaCa-2 (MP2R). In the drug-treated group, the frequencies of the fish showing head, trunk, or end-tail dissemination significantly decreased to 15.3% ± 6.7%, 6.2% ± 1.3%, or 41.1% ± 1.5%; conversely, the frequency of the fish not showing any dissemination significantly increased to 46.3% ± 8.9% when compared with those in the vehicle-treated group; 74.5% ± 11.1%, 18.9% ± 14.9%, 77.0% ± 9.0%, or 17.2% ± 0.7% (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> and <xref ref-type="table" rid="table5">Table 5</xref>).</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Effects of pharmacological inhibition of HTR2C on metastatic dissemination of Mia-PaCa2 cells in zebrafish xenografted models.</title><p>Related to <xref ref-type="fig" rid="fig4">Figure 4</xref>. The numbers and frequencies of the fish showing the dissemination patterns in vehicle- or pizotifen-treated group were indicated. The fish showed both patterns of dissemination were redundantly counted in this analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">Experiment_#1</th><th align="left" valign="bottom">Experiment_#2</th><th align="left" valign="bottom">Average of experiments</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4"> Drug: Vehicle<break/> Cell: MIA-PaCa2</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">17.64% n1 = 3/17</td><td align="left" valign="bottom">16.66% n2 = 2/12</td><td align="left" valign="bottom">17.15% + 0.69%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">82.35% n1 = 14/17</td><td align="left" valign="bottom">66.66% n2 = 8/12</td><td align="left" valign="bottom">74.50% + 11.09%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">29.41% n1 = 5/17</td><td align="left" valign="bottom">8.33% n2 = 1/12</td><td align="left" valign="bottom">18.87% + 14.90%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">70.58% n1 = 12/17</td><td align="left" valign="bottom">83.33% n2 = 10/17</td><td align="left" valign="bottom">76.96% + 9.01</td></tr><tr><td align="left" valign="bottom" rowspan="4"> Drug: Pizotifen<break/> Cell: MIA-PaCa2</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">40% n1 = 4/10</td><td align="left" valign="bottom">52.63% n2 = 10/19</td><td align="left" valign="bottom">46.31% + 8.93%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">20% n1 = 2/10</td><td align="left" valign="bottom">10.52% n2 = 2/19</td><td align="left" valign="bottom">15.26% + 6.69%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">10% n1 = 1/10</td><td align="left" valign="bottom">5.26% n2 = 1/19</td><td align="left" valign="bottom">7.63% + 3.34%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">40% n1 = 4/10</td><td align="left" valign="bottom">42.05% n2 = 8/19</td><td align="left" valign="bottom">41.4% + 1.48%</td></tr></tbody></table></table-wrap><p>To eliminate the possibility that the metastasis suppressing effects of pizotifen might result from off-target effects of the drug, we conducted validation experiments to determine whether knockdown of HTR2C would show the same effects. Sub-clones of 231R cells that expressed short hairpin RNA (shRNA) targeting either LacZ or HTR2C were injected into the fish at 2 dpf and the fish were maintained in the absence of drug. In the fish that were inoculated with shHTR2C 231R cells, the frequencies of the fish showing head, trunk, and end-tail dissemination significantly decreased to 6.7% ± 4.9%, 6.7% ± 0.7%, or 20.0% ± 16.5%; conversely, the frequency of the fish not showing any dissemination significantly increased to 80.0% ± 4.4% when compared with those that were inoculated with shLacZ 231R cells; 80.0% ± 27.1%, 20.0% ± 4.5%, 90.0% ± 7.7%, or 0% (<xref ref-type="fig" rid="fig2">Figure 2E</xref> and <xref ref-type="table" rid="table6">Table 6</xref>).</p><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Effects of genetic inhibition of HTR2C on metastatic dissemination of MDA-MB-231 cells in zebrafish xenografted models.</title><p>Related to <xref ref-type="fig" rid="fig2">Figure 2E</xref>. The numbers and frequencies of the fish showing the dissemination patterns in the zebrafish that were inoculated with either shLacZ or shHTR2C MDA-MB-231 cells were indicated. The fish showed both patterns of dissemination were redundantly counted in this analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">Experiment_#1</th><th align="left" valign="bottom">Experiment_#2</th><th align="left" valign="bottom">Average of experiments</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4"> shLacZ</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">0% n1 = 0/10</td><td align="left" valign="bottom">0% n2 = 0/10</td><td align="left" valign="bottom">0%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">60% n1 = 6/10</td><td align="left" valign="bottom">100% n2 = 10/10</td><td align="left" valign="bottom">80% ± 28.28%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">30% n1 = 3/10</td><td align="left" valign="bottom">10% n2 = 1/10</td><td align="left" valign="bottom">20% ± 14.14%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">80% n1 = 8/10</td><td align="left" valign="bottom">100% n2 = 10/10</td><td align="left" valign="bottom">90% ± 14.14</td></tr><tr><td align="left" valign="bottom" rowspan="4"> shHTR2C</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">80% n1 = 12/15</td><td align="left" valign="bottom">76.84% n2 = 14/19</td><td align="left" valign="bottom">76.84 ± 4.46%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">6.66% n1 = 1/15</td><td align="left" valign="bottom">15.78% n2 = 3/19</td><td align="left" valign="bottom">11.22% ± 6.45%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">6.66% n1 = 1/15</td><td align="left" valign="bottom">5.26% n2 = 1/19</td><td align="left" valign="bottom">5.96% ± 0.99%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">20% n1 = 3/15</td><td align="left" valign="bottom">26.31% n2 = 5/19</td><td align="left" valign="bottom">23.15% ± 4.46%</td></tr></tbody></table></table-wrap><p>These results indicate that pharmacological and genetic inhibition of HTR2C suppressed metastatic dissemination of human cancer cells in vivo.</p></sec><sec id="s2-5"><title>Pizotifen suppressed metastasis progression of a mouse model of metastasis</title><p>We examined the metastasis-suppressor effect of pizotifen in a mouse model of metastasis (<xref ref-type="bibr" rid="bib101">Tao et al., 2008</xref>). Luciferase-expressing 4T1 murine mammary carcinoma cells were inoculated into the mammary fat pads (MFP) of female BALB/c mice. On day 2 post inoculation, the mice were randomly assigned to two groups and one group received once daily intraperitoneal injections of 10 mg/kg pizotifen while the other group received a vehicle injection. Bioluminescence imaging and tumor measurement revealed that the sizes of the primary tumors in pizotifen-treated mice were equal to those in the vehicle-treated mice on day 10 post inoculation. The primary tumors were resected after the analyses. Immunofluorescence (IF) staining also demonstrated that the percentage of Ki67-positive cells in the resected primary tumors of pizotifen-treated mice were the same as those of vehicle-treated mice (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>), additionally, both groups showed less than 1% cleaved caspase 3 positive cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Therefore, no anti-tumor effect of pizotifen was observed on the primary tumor. After 70 days from inoculation, bioluminescence imaging detected light emitted in the lungs, livers, and lymph nodes of vehicle-treated mice but not those of pizotifen-treated mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Vehicle-treated mice formed 5–50 metastatic nodules per lung in all 10 mice analyzed; conversely, pizotifen-treated mice (n = 10) formed 0–5 nodules per lung in all 10 mice analyzed (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Histological analyses confirmed that metastatic lesions in the lungs were detected in all vehicle-treated mice; conversely, they were detected in only 2 of 10 pizotifen-treated mice and the rest of the mice showed metastatic colony formations around the bronchiole of the lung. In addition, 4 of 10 vehicle-treated mice exhibited metastasis in the liver and the rest showed metastatic colony formation around the portal tract of the liver. In contrast, none of 10 pizotifen-treated mice showed liver metastases and only half of the 10 mice showed metastatic colony formation around the portal tract (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). These results indicate that pizotifen can suppress metastasis progression without affecting primary tumor growth.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Pizotifen suppressed metastatic progression in a mouse model of metastasis.</title><p>(<bold>A</bold>) Mean volumes (n = 10 per group) of 4T1 primary tumors formed in the mammary fat pad of either vehicle- or pizotifen-treated mice at day 10 post injection. (<bold>B</bold>) Ki67 expression level in 4T1 primary tumors formed in the mammary fat pad of either vehicle- or pizotifen-treated mice at day 10 post injection. The mean expression levels of Ki67 (n = 10 mice per group) were determined and were calculated as the mean ration of Ki67-positive cells to 4’,6-diamidino-2-phenylindole (DAPI) area. (<bold>C</bold>) Representative images of primary tumors on day 10 post injection (top panels) and metastatic burden on day 70 post injection (bottom panels) taken using an IVIS Imaging System. (<bold>D</bold>) Representative images of the lungs from either vehicle- (top) or pizotifen-treated mice (bottom) at 70 days post tumor inoculation. Number of metastatic nodules in the lung of either vehicle- or pizotifen-treated mice (right). (<bold>E</bold>) Representative hematoxylin and eosin (H&amp;E) staining of the lung (top) and liver (bottom) from either vehicle- or pizotifen-treated mice. Black arrow heads indicate metastatic 4T1 cells. (<bold>F</bold>) The mean number of metastatic lesions in step sections of the lungs from the mice that were inoculated with 4T1-12B cells expressing short hairpin RNA (shRNA) targeting for either LacZ or HTR2C. (<bold>G</bold>) Representative H&amp;E staining of the lung and liver from the mice that were inoculated with 4T1-12B cells expressing shRNA targeting for either LacZ or HTR2C. Black arrow heads indicate metastatic 4T1 cells. Each value is indicated as the mean ± SEM. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig3-v4.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cleaved caspase 3 expression level in 4T1 primary tumors formed in the mammary fat pad of either vehicle- or pizotifen-treated mice at day 10 post injection.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig3-figsupp1-v4.tif"/></fig></fig-group><p>To eliminate the possibility that the metastasis suppressing effects of pizotifen might result from off-target effects, we conducted validation experiments to determine whether knockdown of HTR2C would show the same effects. The basic experimental process followed the experimental design described above except that sub-clones of 4T1 cells that expressed shRNA targeting either LacZ or HTR2C were injected into the MFP of female BALB/c mice and the mice were maintained without drug. Histological analyses revealed that all of the mice (n = 5) that were inoculated with 4T1 cells expressing shRNA targeting LacZ showed metastases in the lungs. The mean number of metastatic lesions in a lung was 26.4 ± 7.8. In contrast, only one of the mice (n = 5) were inoculated with 4T1 cells expressing shRNA targeting HTR2C showed metastases in the lungs and the rest of the mice showed metastatic colony formation around the bronchiole of the lung. The mean number of metastatic lesions in the lung significantly decreased to 10% of those of mice that were inoculated with 4T1 cells expressing shRNA targeting LacZ (<xref ref-type="fig" rid="fig3">Figure 3F–H</xref>).</p><p>Taken together, pharmacological and genetic inhibition of HTR2C showed an anti-metastatic effect in the 4T1 model system.</p></sec><sec id="s2-6"><title>HTR2C promoted EMT-mediated metastatic dissemination of human cancer cells</title><p>Although pharmacological and genetic inhibition of HTR2C inhibited metastasis progression, a role for HTR2C on metastatic progression has not been reported. Therefore, we examined whether HTR2C could confer metastatic properties on poorly metastatic cells.</p><p>First, we established a stable sub-clone of MCF7 human breast cancer cells expressing either vector control or HTR2C. Vector control expressing MCF7 cells maintained highly organized cell-cell adhesion and cell polarity; however, HTR2C-expressing MCF7 cells led to loss of cell-cell contact and cell scattering. The cobblestone-like appearance of these cells was replaced by a spindle-like, fibroblastic morphology. Western blotting and IF analyses revealed that HTR2C-expressing MCF7 cells showed loss of E-cadherin and EpCAM, and elevated expressions of N-cadherin, vimentin, and an EMT-inducible transcriptional factor ZEB1. Similar effects were validated through another experiment using an immortal keratinocyte cell line, HaCaT cells, in that HTR2C-expressing HaCaT cells also showed loss of cell-cell contact and cell scattering with loss of epithelial markers and gain of mesenchymal markers (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Therefore, both the morphological and molecular changes in the HTR2C-expressing MCF7 and HaCaT cells demonstrated that these cells had undergone an EMT.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>HTR2C induced epithelial-to-mesenchymal transition (EMT)-mediated metastatic dissemination of human cancer cells.</title><p>(<bold>A</bold>) The morphologies of the MCF7 and HaCaT cells expressing either the control vector or HTR2C were revealed by phase contrast microscopy. (<bold>B</bold>) Immunofluorescence staining of E-cadherin, EpCAM, vimentin, and N-cadherin expressions in the MCF7 cells from A. (<bold>C</bold>) Expression of E-cadherin, EpCAM, vimentin, N-cadherin, and HTR2C was examined by western blotting in the MCF7 and HaCaT cells; GAPDH loading control is shown (bottom). (<bold>D</bold>) Effect of HTR2C on cell motility and invasion of MCF7 cells. MCF7 cells were subjected to Boyden chamber assays. Fetal bovine serum (1% v/v) was used as the chemoattractant in both assays. Each experiment was performed at least twice. (<bold>E</bold>) Representative images of dissemination patterns of MCF7 cells expressing either the control vector (top left) or HTR2C (lower left) in a zebrafish xenotransplantation model. White arrow heads indicate disseminated MCF7 cells. The mean frequencies of the fish showing head, trunk, or end-tail dissemination tabulated (right). Each value is indicated as the mean ± SEM of two independent experiments. Statistical analysis was determined by Student’s t test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig4-v4.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>HTR2C promoted EMT-mediated metastatic dissemination of poorly metastatic human cancer cells in a zebrafish xenotransplantation model.</title><p>(<bold>A</bold>) Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. The analyses were performed by ImageJ. Signal strength of bands of E-cadherin, EpCAM, N-cadherin, vimentin, ZEB1, and HTR2C was normalized by that of GAPDH. (<bold>B</bold>) Representative images of dissemination patterns of MCF7 cells expressing either the control vector (top left, middle left, bottom left) or HTR2C (top right, middle right, bottom right) in a zebrafish xenotransplantation model.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig4-figsupp1-v4.tif"/></fig></fig-group><p>Next, we examined whether HTR2C-driven EMT could promote metastatic dissemination of human cancer cells. Boyden chamber assay revealed that HTR2C expressing MCF7 cells showed an increased cell motility and invasion compared with vector control-expressing MCF7 cells in vitro (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Moreover, we conducted in vivo examination of whether HTR2C expression could promote metastatic dissemination of human cancer cells in a zebrafish xenotransplantation model. RFP-labelled MCF7 cells expressing either vector control or HTR2C were injected into the duct of Cuvier of <italic>Tg</italic> (<italic>kdrl:eGFP</italic>) zebrafish at 2 dpf. Twenty-four hours post injection, the frequencies of the fish showing metastatic dissemination of the inoculated cells were measured using fluorescence microscopy. In the fish that were inoculated with HTR2C expressing MCF7 cells, the frequencies of the fish showing head, trunk, and end-tail dissemination significantly increased to 96.7% ± 4.7%, 68.8% ± 6.4%, or 89.5% ± 3.4%; conversely, the frequency of the fish not showing any dissemination decreased to 0% when compared with those in the fish that were inoculated with vector control expressing MCF7 cells; 33.1% ± 18.5%, 0%, 56.9% ± 4.4%, or 43% (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> and <xref ref-type="table" rid="table7">Table 7</xref>).</p><table-wrap id="table7" position="float"><label>Table 7.</label><caption><title>Effects of HTR2C overexpression on metastatic dissemination of MCF7 cells in zebrafish xenografted models.</title><p>Related to <xref ref-type="fig" rid="fig4">Figure 4E</xref>. The numbers and frequencies of the fish showing the dissemination patterns in the zebrafish that were inoculated with MCF7 cells expressing either vector control (VC) or HTR2C were indicated. The fish showed both patterns of dissemination were redundantly counted in this analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">Experiment_#1</th><th align="left" valign="bottom">Experiment_#2</th><th align="left" valign="bottom">Average of experiments</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4">VC</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">46.15% n1 = 6/13</td><td align="left" valign="bottom">40% n2 = 4/10</td><td align="left" valign="bottom">43.07% ± 4.35%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">46.15% n1 = 6/13</td><td align="left" valign="bottom">20% n2 = 2/10</td><td align="left" valign="bottom">33.07% ± 18.49%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">0% n1 = 0/13</td><td align="left" valign="bottom">0% n2 = 0/10</td><td align="left" valign="bottom">0%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">53.84% n1 = 7/13</td><td align="left" valign="bottom">60% n2 = 6/10</td><td align="left" valign="bottom">56.92% ± 4.35%</td></tr><tr><td align="left" valign="bottom" rowspan="4">HTR2C</td><td align="left" valign="bottom">Non-dissemination</td><td align="left" valign="bottom">0% n1 = 0/14</td><td align="left" valign="bottom">0% n2 = 0/15</td><td align="left" valign="bottom">0%</td></tr><tr><td align="left" valign="bottom">Head</td><td align="left" valign="bottom">100% n1 = 14/14</td><td align="left" valign="bottom">93.33% n2 = 14/15</td><td align="left" valign="bottom">96.66% ± 4.71%</td></tr><tr><td align="left" valign="bottom">Trunk</td><td align="left" valign="bottom">64.28% n1 = 9/14</td><td align="left" valign="bottom">73.33% n2 = 11/15</td><td align="left" valign="bottom">68.80% ± 6.39%</td></tr><tr><td align="left" valign="bottom">End-tail</td><td align="left" valign="bottom">85.71% n1 = 12/14</td><td align="left" valign="bottom">93.33% n2 = 14/15</td><td align="left" valign="bottom">89.52% ± 5.38%</td></tr></tbody></table></table-wrap><p>These results indicated that HTR2C promoted metastatic dissemination of cancer cells through induction of EMT, and suggest that the screen can easily be converted to a chemical genetic screening platform.</p></sec><sec id="s2-7"><title>Pizotifen induced mesenchymal-to-epithelial transition through inhibition of Wnt signaling</title><p>Finally, we elucidated the mechanism of action of how pizotifen suppressed metastasis, especially metastatic dissemination of cancer cells. Our results showed that HTR2C induced EMT and that pharmacological and genetic inhibition of HTR2C suppressed metastatic dissemination of MDA-MB-231 cells that had already transitioned to mesenchymal-like traits via EMT. Therefore, we speculated that blocking HTR2C with pizotifen might inhibit the molecular mechanisms which follow EMT induction. We first investigated the expressions of epithelial and mesenchymal markers in pizotifen-treated MDA-MB-231 cells since the activation of an EMT program needs to be transient and reversible, and transition from a fully mesenchymal phenotype to a epithelial-mesenchymal hybrid state or a fully epithelial phenotype is associated with malignant phenotypes (<xref ref-type="bibr" rid="bib41">Kröger et al., 2019</xref>). IF and FACS analyses revealed 20% of pizotifen-treated MDA-MB-231 cells restored E-cadherin expression. Also, western blotting analysis demonstrated that 4T1 primary tumors from pizotifen-treated mice has elevated E-cadherin expression compared with tumors from vehicle-treated mice (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). However, mesenchymal markers did not change between vehicle and pizotifen-treated MDA-MB-231 cells (data not shown). We further analyzed E-cadherin-positive (E-cad<sup>+</sup>) cells in pizotifen-treated MDA-MB-231 cells. The E-cad<sup>+</sup> cells showed elevated expressions of epithelial markers KRT14 and KRT19; and decreased expression of mesenchymal makers vimentin, MMP1, MMP3, and S100A4. Recent research reports that an EMT program needs to be transient and reversible and that a mesenchymal phenotype in cancer cells is achieved by constitutive ectopic expression of ZEB1. In accordance with the research, the E-cad<sup>+</sup> cells and 4T1 primary tumors from pizotifen-treated mice had decreased ZEB1 expression compared with vehicle-treated cells and tumors from vehicle-treated mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). In contrast, HTR2C-expressing MCF7 and HuMEC cells expressed ZEB1 but not vehicle control MCF7 and HuMEC cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). HTR2C-expressing MCF7 cells expressed not only ZEB1 but also Twist1 and Snail. In contrast, pizotifen-treated MDA-MB-231 cells showed decreased expression of ZEB1 and Twist1 compared with that in vehicle-treated cells. Furthermore, in the primary tumors of pizotifen-treated mice, only ZEB1 expression was decreased compared with those of vehicle-treated mice. These results indicate that HTR2C-mediated signaling induced EMT through up-regulation of ZEB1 and blocking HTR2C with pizotifen induced mesenchymal-to-epithelial transition through down-regulation of ZEB1 (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Pizotifen restored mesenchymal-like traits of MDA-MB-231 cells into epithelial traits through blocking nuclear accumulation of β-catenin.</title><p>(<bold>A</bold>) Immunofluorescence (IF) staining of E-cadherin in either vehicle- or pizotifen-treated MDA-MB-231 cells. (<bold>B</bold>) Surface expression of E-cadherin in either vehicle (black)- or pizotifen (red)-treated MDA-MB-231 cells by FACS analysis. Non-stained controls are shown in gray. (<bold>C</bold>) Protein expressions levels of E-cadherin, ZEB1, and β-catenin in the cytoplasm and nucleus of 4T1 primary tumors from either vehicle- or pizotifen-treated mice are shown; Luciferase, histone H3, and β-tubulin are used as loading control for whole cell, nuclear, or cytoplasmic lysate, respectively. (<bold>D</bold>) Protein expression levels of epithelial and mesenchymal markers and ZEB1 in either vehicle- or pizotifen-treated MDA-MB-231 cells or E-cadherin-positive (E-cad<sup>+</sup>) cells in pizotifen-treated MDA-MB-231 cells are shown. (<bold>E</bold>) IF staining of β-catenin in the MCF7 cells expressing either vector control (top left, bottom left) or HTR2C (top right, bottom right). (<bold>F</bold>) Expressions of β-catenin in the cytoplasm and nucleus of MCF7 cells. (<bold>G</bold>) IF staining of β-catenin in either vehicle (top left, bottom left) or pizotifen-treated MDA-MB-231 cells (top right, bottom right). (<bold>H</bold>) Expressions of β-catenin in the cytoplasm and nucleus of MDA-MB-231 cells and the E-cad<sup>+</sup> cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-v4.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title><p>The analyses were performed by ImageJ. Signal strength of bands of E-cadherin, EpCAM, p-GSK-3β, GSK-3β were normalized by that of luciferase. Signal strength of bands of nuclear and cytoplasmic β-catenin was normalized by that of histone H3 and β-tubulin, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-figsupp1-v4.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title><p>The analyses were performed by ImageJ. Signal strength of bands of E-cadherin, EpCAM, KRT18, KRT19, MMP1, MMP3, vimentin, and S100A4 was normalized by that of GAPDH.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-figsupp2-v4.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig5">Figure 5F</xref>.</title><p>The analyses were performed by ImageJ. Signal strength of bands of nuclear and cytoplasmic β-catenin was normalized by that of histone H3 and β-tubulin, respectively. Signal strength of bands of p-GSK-3β and GSK-3β was normalized by that of GAPDH.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-figsupp3-v4.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Expression of Snail and Twist1 was examined by western blotting in the MCF7 cells (left); GAPDH loading control is shown (bottom).</title><p>GAPDH band is the same as one from <xref ref-type="fig" rid="fig4">Figure 4C</xref> since GAPDH bands in <xref ref-type="fig" rid="fig4">Figure 4C</xref> (bottom left) and Figure 5—figure supplement 4 (bottom left) were obtained in the same experiment. Protein expression levels of Twist1 in either vehicle- or pizotifen-treated MDA-MB-231 cells are shown (middle): GAPDH loading control is shown (bottom). Protein expression levels of Snail and Twist1 of 4T1 primary tumors from either vehicle- or pizotifen-treated mice are shown (right); luciferase is used as loading control for whole cell. Luciferase control was obtained in the same experiment from <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-figsupp4-v4.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>Quantification analyses of western blotting bands in <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title><p>The analyses were performed by ImageJ. Signal strength of bands of nuclear and cytoplasmic β-catenin was normalized by that of histone H3 and β-tubulin, respectively. Signal strength of bands of p-GSK-3β and GSK-3β was normalized by that of GAPDH.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-70151-fig5-figsupp5-v4.tif"/></fig></fig-group><p>We further investigated the mechanism of action of how blocking HTR2C with pizotifen induced down-regulation of ZEB1. In embryogenesis, serotonin-mediated signaling is required for Wnt-dependent specification of the superficial mesoderm during gastrulation (<xref ref-type="bibr" rid="bib6">Beyer et al., 2012</xref>). Wnt signaling plays critical role in inducing EMT. In cancer cells, overexpression of HTR1D is associated with Wnt signaling (<xref ref-type="bibr" rid="bib98">Sui et al., 2015</xref>; <xref ref-type="bibr" rid="bib126">Zhan et al., 2017</xref>). This evidence led to a hypothesis that HTR2C-mediated signaling might turn on transcriptional activity of β-catenin and that might induce up-regulation of EMT-TFs. IF analyses revealed β-catenin was accumulated in the nucleus of HTR2C-expressing MCF7 cells but it was located in the cytoplasm of vector control-expressing cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Nuclear accumulation of β-catenin in HTR2C-expressing MCF7 cells was confirmed by western blot (<xref ref-type="fig" rid="fig5">Figure 5F</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). In contrast, pizotifen-treated MDA-MB-231 cells showed β-catenin located in the cytoplasm of the cells. Vehicle-treated cells showed that β-catenin accumulated in the nucleus of the cells. (<xref ref-type="fig" rid="fig5">Figure 5G</xref>), and western blotting analysis confirmed that it was located in the cytoplasm of pizotifen-treated MDA-MB-231 cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref> and <xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>). Furthermore, immunohistochemistry and western blotting analyses showed that β-catenin accumulated in the nucleus, and phospho-GSKβ and ZEB1 expression were decreased in 4T1 primary tumors from pizotifen-treated mice compared with vehicle-treated mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). These results indicated that HTR2C would regulate transcriptional activity of β-catenin and pizotifen could inhibit it.</p><p>Taken together, we conclude that blocking HTR2C with pizotifen restored epithelial properties to metastatic cells (MDA-MB-231 and 4T1 cells) through a decrease of transcriptional activity of β-catenin and that suppressed metastatic progression of the cells.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Reducing or eliminating mortality associated with metastatic disease is a key goal of medical oncology, but few models exist that allow for rapid, effective screening of novel compounds that target the metastatic dissemination of cancer cells. Based on accumulated evidence that at least 50 genes play an essential role in governing both metastasis and gastrulation progression (<xref ref-type="table" rid="table1">Table 1</xref>), we hypothesized that small molecule inhibitors that interrupt gastrulation of zebrafish embryos might suppress metastatic progression of human cancer cells. We created a unique screening concept utilizing gastrulation of zebrafish embryos to test the hypothesis. Our results clearly confirmed our hypothesis: 25.6% (20/76 drugs) of epiboly-interrupting drugs could also suppress cell motility and invasion of highly metastatic human cell lines in vitro. In particular, pizotifen, which is an antagonist for serotonin receptor 2C and one of the epiboly-interrupting drugs, could suppress metastasis in a mouse model (<xref ref-type="fig" rid="fig3">Figure 3A–E</xref>). Thus, this screen could offer a novel platform for discovery of anti-metastasis drugs.</p><p>Among the 20 drugs which suppressed both epiboly progression and cell motility and invasion of MDA-MB-231 cells, hexachlorophene and troglitazone showed the strongest effect on suppressing cell motility and invasion of MDA-MB-231 cells. However, the drug could not suppress cell motility and invasion of other highly metastatic human cancer cell lines: MDA-MB-435 and PC3. With the exception of pizotifen and S(-)eticlopride hydrochloride, the remaining 18 drugs could not show the suppressor effect on more than three highly metastatic human cancer cell lines. These results indicate that the strength of interrupting effect of a drug on epiboly progression is not proportional to the strength of suppressing effect of the drug on metastasis.</p><p>We have provided the first evidence that HTR2C, which is a primary target of pizotifen, induced EMT and promoted metastatic dissemination of cancer cells (<xref ref-type="fig" rid="fig4">Figure 4A–E</xref>). Clinical data shows that HTR2C expression is correlated with tumor stage of breast cancer patients and is higher in metastatic and Her2/neu-overexpressing tumors (<xref ref-type="bibr" rid="bib76">Pai et al., 2009</xref>). That would support our finding.</p><p>Pharmacological inhibition of DRD2 with S(-)eticlopride hydrochloride suppressed cell invasion and migration of multiple human cancer cell lines in vitro. However, overexpression of DRD2 could not induce EMT on MCF7 cells. Therefore, we stopped focusing on DRD2 and S(-)eticlopride hydrochloride.</p><p>There are at least two advantages to the screen described herein. One is that the screen can easily be converted to a chemical genetic screening platform. Indeed, our screen succeeded to identify HTR2C as an EMT inducer (<xref ref-type="fig" rid="fig4">Figure 4A–E</xref>). In this research, 1280 FDA approval drugs were screened, this is less than a few percent of all of druggable targets (approximately 100 targets) in the human proteome in the body. If chemical genetic screening using specific inhibitor libraries were conducted, more genes that contribute to metastasis and gastrulation could be identified. The second advantage is that the screen enables one researcher to test 100 drugs in 5 hr with using optical microscopy, drugs, and zebrafish embryos. That indicates this screen is not only highly efficient, low-cost, and low-labor but also enables researchers who do not have high-throughput screening instruments to conduct drug screening for anti-metastasis drugs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (Zebrafish)</td><td align="left" valign="bottom">AB line</td><td align="left" valign="bottom">National University of Singapore</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (Zebrafish)</td><td align="left" valign="bottom"><italic>Tg (kdrl:eGFP</italic>) zebrafish</td><td align="left" valign="bottom">Provided by Dr Stainier</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">BALB/c</td><td align="left" valign="bottom">Charles River Laboratories</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-231</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-26</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MCF7</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-22</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-435</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-129</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MIA-PaCa2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRM-CRL-1420</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PC3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3471</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">SW620</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-227</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PC9</td><td align="left" valign="bottom">RIKEN BRC</td><td align="left" valign="bottom">RCB0446</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HaCaT</td><td align="left" valign="bottom">CLI</td><td align="char" char="." valign="bottom">300493</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (BALB/c Mus)</td><td align="char" char="hyphen" valign="bottom">4T1-12B</td><td align="left" valign="bottom">Provided from Dr Gary Sahagian</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PRMT1 (A33)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_2449</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CYP11A1 (D8F4F)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_14217</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">E-cadherin (4A2)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_14472</td><td align="left" valign="bottom">WB (1:1000)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">EpCAM (VU1D9)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_2929</td><td align="left" valign="bottom">WB (1:1000)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Vimentin (D21H3)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_5741</td><td align="left" valign="bottom">WB (1:1000)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">N-cadherin (D4R1H)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_13116</td><td align="left" valign="bottom">WB (1:1000)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ZEB1 (D80D3)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_3396</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Histone H3 (D1H2)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_4499</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-Tubulin (9F3)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_2128</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH (14C10)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#_2118</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HTR2C (ab133570)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#_ab133570</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DRD2 (ab85367)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#_ab85367</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-GSK3β (Ser9) (F-2)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-373800</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GSK3β (1F7)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-53931</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">KRT18 (DC-10)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-6259</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">KRT19 (A53-B/A2)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-6278</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MMP1 (3B6)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-21731</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MMP2 (8B4)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-13595</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">S100A4 (A-7)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-377059</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Luciferase (C-12)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-74548</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ki67 (ki-67)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-23900</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-Catenin (E-5)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-7963</td><td align="left" valign="bottom">WB (1:1000)<break/>IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC-conjugated E-cadherin antibody (67A4)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat#_324104</td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse anti-rabbit immunoglobulin G (IgG) antibodies conjugated to Alexa Fluor 488</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A-11029</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-goat anti-rabbit immunoglobulin G (IgG) antibodies conjugated to Alexa Fluor 488</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A-11034</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLVX-shRNA1</td><td align="left" valign="bottom">Clontech</td><td align="left" valign="bottom">Cat#_ 632,177</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCDH-CMV-MCS-EF1α-Hygro</td><td align="left" valign="bottom">System Biosciences</td><td align="left" valign="bottom">Cat#_CD515B-1</td><td align="left" valign="bottom">Gene expression vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMDLg/pRRE</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene Plasmid #12251 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12251">Addgene_12251</ext-link></td><td align="left" valign="bottom">Lentivirus packaging vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRSV-rev</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene Plasmid #12253 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12253">Addgene_12253</ext-link></td><td align="left" valign="bottom">Lentivirus packaging vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMD2.G</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene Plasmid #12259 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12259">Addgene_12259</ext-link></td><td align="left" valign="bottom">Lentivirus packaging vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Providing pCMV-h5TH2C-VSV</td><td align="left" valign="bottom">Provided from Dr Herrick</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FDA-approved chemical libraries</td><td align="left" valign="bottom">Prestwick Chemical</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pizotifen</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_sc-201143</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">S(-)Eticlopride hydrochloride</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#_E101</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism7</td><td align="left" valign="bottom">GraphPad Software Inc</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom">Data analysis</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom">FACS data analysis</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Zebrafish embryo screening</title><p>Zebrafish embryos at two-cell stage were collected at 20 min after their fertilization. Each drug was added to a well of a 24-well plate containing approximately 20 zebrafish embryos per well in either 10 or 50 μM final concentration when the embryos reached the sphere stage. Chemical treatment was initiated at 4 hpf and approximately 20 embryos were treated with two different concentrations for each compound tested. The treatment was ended at 9 hpf when vehicle- (DMSO) treated embryos as control reach 80–90% completion of the epiboly stage. The compounds which induced delay (&lt;50% epiboly) in epiboly were selected as hit compounds for in vitro testing using highly metastatic human cancer cell lines. The study protocol was approved by the Institutional Animal Care and Use Committee of the National University of Singapore (protocol number: R16-1068).</p></sec><sec id="s4-2"><title>Reagents</title><p>FDA, EMA, and other agencies-approved chemical libraries were purchased from Prestwick Chemical (Illkirch, France). Pizotifen (sc-201143) and S(-)eticlopride hydrochloride (E101) were purchased from Santa Cruz (Dallas, TX) and Sigma-Aldrich (St Louis, MO).</p></sec><sec id="s4-3"><title>Cell culture and cell viability assay</title><p>MCF7, MDA-MB-231, MDA-MB-435, MIA-PaCa2, PC3, SW620, PC9, and HaCaT cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Luciferase-expressing 4T1 (4T1-12B) cells were provided from Dr Gary Sahagian (Tufts University, Boston, MA). All culture methods followed the supplier’s instruction. Cell viability assay was performed as previously described (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>). PCR-based mycoplasma testing on these cells was performed once in 4 months.</p></sec><sec id="s4-4"><title>Plasmid</title><p>A DNA fragment coding for HTR2C was amplified by PCR with primers containing restriction enzyme recognition sequences. The HTR2C coding fragment was amplified from hsp70l:mCherry-T2A-CreERT2 plasmid (<xref ref-type="bibr" rid="bib29">Huang et al., 2012</xref>).</p></sec><sec id="s4-5"><title>Immunoblotting</title><p>Western blotting was performed as described previously (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>). Raw data of images of western blotting analyses are uploaded as source data for western. Anti-PRMT1 (A33), anti-CYP11A1 (D8F4F), anti-E-cadherin (4A2), anti-EpCAM (VU1D9), anti-vimentin (D21H3), anti-N-cadherin (D4R1H), anti-ZEB1 (D80D3), anti-histone H3 (D1H2), anti-β-tubulin (9F3), and anti-GAPDH (14C10) antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-HTR2C (ab133570) and anti-DRD2 (ab85367) antibodies were purchased form Abcam (Cambridge, UK). Anti-phospho-GSK3β (Ser9) (F-2), anti-GSK3β (1F7), anti-KRT18 (DC-10), anti-KRT19 (A53-B/A2), anti-MMP1 (3B6), anti-MMP2 (8B4), anti-S100A4 (A-7), anti-luciferase (C-12), anti-ki67 (ki-67), and anti-β-catenin (E-5) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX).</p></sec><sec id="s4-6"><title>Flow cytometry</title><p>Cells were stained with FITC-conjugated E-cadherin antibody (67A4, Biolegend, San Diego, CA). Flow cytometry was performed as described (<xref ref-type="bibr" rid="bib68">Nakayama et al., 2009</xref>) and analyzed with FlowJo software (TreeStar, Ashland, OR).</p></sec><sec id="s4-7"><title>shRNA-mediated gene knockdown</title><p>The shRNA-expressing lentivirus vectors were constructed using pLVX-shRNA1 vector (632177, TAKARA Bio, Shiga, Japan). PRMT1-shRNA_#3-targeting sequence is <named-content content-type="sequence">GTGTTCCAGTATCTCTGATTA</named-content>; PRMT1-shRNA_#4-targeting sequence is <named-content content-type="sequence">TTGACTCCTACGCACACTTTG</named-content>. CYP11A1-shRNA_#4-targeting sequence is <named-content content-type="sequence">GCGATTCATTGATGCCATCTA</named-content>; CYP11A1-shRNA_#4-targeting sequence is <named-content content-type="sequence">GAAATCCAACACCTCAGCGAT</named-content>. Human HTR2C-shRNA-targeting sequence is <named-content content-type="sequence">TCATGCACCTCTGCGCTATAT</named-content>. Mouse HTR2C-shRNA-targeting sequence is <named-content content-type="sequence">CTTCATACCGCTGACGATTAT</named-content>. LacZ-shRNA-targeting sequence is <named-content content-type="sequence">CTACACAAATCAGCGATT</named-content>.</p></sec><sec id="s4-8"><title>Immunofluorescence</title><p>IF microscopy assay was performed as previously described (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>). Goat anti-mouse and goat anti-rabbit immunoglobulin G (IgG) antibodies conjugated to Alexa Fluor 488 (A-11029 and A-11034, Life Technologies, Carlsbad, CA) and diluted at 1:100 were used. Nuclei were visualized by the addition of 2 μg/ml of 4’,6-diamidino-2-phenylindole (DAPI) (62248, Thermo Fisher, Waltham, MA) and photographed at 100× magnification by a fluorescent microscope BZ-X700 (KEYENCE, Osaka, Japan).</p></sec><sec id="s4-9"><title>Boyden chamber cell motility and invasion assay</title><p>These assays were performed as previously described (<xref ref-type="bibr" rid="bib69">Nakayama et al., 2020</xref>). In Boyden chamber assay, either 3 × 10<sup>5</sup> MDA-MB-231, 1 × 10<sup>6</sup> MDA-MB-435 or 5 × 10<sup>5</sup> PC9 cells were applied to each well in the upper chamber.</p></sec><sec id="s4-10"><title>Zebrafish xenotransplantation model</title><p><italic>Tg(kdrl:eGFP</italic>) zebrafish was provided by Dr Stainier (Max Planck Institute for Heart and Lung Research). Embryos that were derived from the line were maintained in E3 medium containing 200 μM 1-phenyl-2-thiourea (P7629, Sigma-Aldrich, St Louis, MO). Approximately 100–400 RFP-labelled MBA-MB-231 or MIA-PaCa2 cells were injected into the duct of Cuvier of the zebrafish at 2 dpf. The fish were randomly assigned to two groups. One group was maintained in the presence of pizotifen-containing E3 medium and the other group was maintained in vehicle-containing E3 medium.</p></sec><sec id="s4-11"><title>Spontaneous metastasis mouse model</title><p>4T1-12B cells (2 × 10<sup>4</sup>) were injected into the #4 MFP while the mice were anesthetized. To monitor tumor growth and metastases, mice were imaged biweekly by IVIS Imaging System (ParkinElmer, Waltham, MA). The primary tumor was resected 10 days after inoculation. D-Luciferin Potassium Salt (LUCK-100) was purchased from GoldBio (St Louis, MO). The study protocol (protocol number: BRC IACUC #110612) was approved by A*STAR (Agency for Science, Technology and Research, Singapore).</p></sec><sec id="s4-12"><title>Gene set enrichment analysis</title><p>Gene expression profiles obtained from zebrafish embryos at either 50%-epiboly, shield, or 75%-epiboly stage were analyzed based on the hallmark gene sets derived from the Molecular Signatures Database (MSigDB) (<xref ref-type="bibr" rid="bib97">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib48">Liberzon et al., 2015</xref>). The zebrafish transcriptomic data was sourced from <xref ref-type="bibr" rid="bib116">White et al., 2017</xref>. Gene sets that were significantly enriched (FDR &lt; 0.25) were presented with the normalized enrichment score (NES) and nominal p value. Source data files for analysis of either gene expression and enriched pathways are uploaded as GSEA <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref> and <xref ref-type="supplementary-material" rid="sdata2">2</xref>, respectively.</p></sec><sec id="s4-13"><title>Histological analysis</title><p>All OCT-embedded primary tumors, lungs, and livers of mice from the spontaneous metastasis 4T1 model were sectioned on a cryostat. Eight micron sections were taken at 500 µm intervals through the entirety of the livers and lungs. Sections were subsequently stained with hematoxylin and eosin. Metastatic lesions were counted under a microscope in each section for both lungs and livers.</p></sec><sec id="s4-14"><title>Statistics</title><p>Data were analyzed by Student’s t test; p &lt; 0.05 was considered significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Validation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Funding acquisition, Project administration, Resources</p></fn><fn fn-type="con" id="con5"><p>Funding acquisition, Resources</p></fn><fn fn-type="con" id="con6"><p>Funding acquisition, Project administration, Resources</p></fn><fn fn-type="con" id="con7"><p>Funding acquisition, Project administration, Resources, Supervision</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The study protocol using zebrafish was approved by the Institutional Animal Care and Use Committee of the National University of Singapore (protocol number: R16-1068). The study protocol using mice (protocol number: BRC IACUC #110612) was approved by A*STAR (Agency for Science, Technology and Research, Singapore).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-70151-transrepform1-v4.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>GSEA analysis of zebrafish embryos at either 50%-epiboly, shield or 75%-epiboly stage.</title></caption><media xlink:href="elife-70151-data1-v4.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Enriched pathways of zebrafish embryos at either 50%-epiboly, shield or 75%-epiboly stage.</title></caption><media xlink:href="elife-70151-data2-v4.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>Raw data of western-blotting analysis.</title></caption><media xlink:href="elife-70151-data3-v4.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata4"><label>Source data 4.</label><caption><title>Raw data of western-blotting analysis with legends.</title></caption><media xlink:href="elife-70151-data4-v4.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We sincerely appreciate Dr Joshua Collins (NIH/NIDCR) and Dr Shimada (Mie University) for helping this research. We thank Dr Herrick (Albany Medical College) for providing pCMV-h5TH2C-VSV with us. This study was funded by grants from National Medical Research Council of Singapore (R-154000547511) and Ministry of Education of Singapore (R-154000A23112) to ZG.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulghani</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Dagvadorj</surname><given-names>A</given-names></name><name><surname>Lutz</surname><given-names>J</given-names></name><name><surname>Leiby</surname><given-names>B</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name><name><surname>Zellweger</surname><given-names>T</given-names></name><name><surname>Alanen</surname><given-names>K</given-names></name><name><surname>Mirtti</surname><given-names>T</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Nevalainen</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Stat3 promotes metastatic progression of prostate cancer</article-title><source>The American Journal of Pathology</source><volume>172</volume><fpage>1717</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.071054</pub-id><pub-id pub-id-type="pmid">18483213</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkers</surname><given-names>J</given-names></name><name><surname>Kramer</surname><given-names>C</given-names></name><name><surname>Pothof</surname><given-names>J</given-names></name><name><surname>Quaedvlieg</surname><given-names>NEM</given-names></name><name><surname>Spaink</surname><given-names>HP</given-names></name><name><surname>Hammerschmidt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Has2 is required upstream of Rac1 to govern dorsal migration of lateral cells during zebrafish gastrulation</article-title><source>Development</source><volume>131</volume><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1242/dev.00954</pub-id><pub-id pub-id-type="pmid">14729574</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barraclough</surname><given-names>J</given-names></name><name><surname>Hodgkinson</surname><given-names>C</given-names></name><name><surname>Hogg</surname><given-names>A</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Welman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells</article-title><source>Neoplasia</source><volume>9</volume><fpage>745</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1593/neo.07442</pub-id><pub-id pub-id-type="pmid">17898870</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname><given-names>E</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Monfar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/35000034</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besser</surname><given-names>J</given-names></name><name><surname>Leito</surname><given-names>JTD</given-names></name><name><surname>van der Meer</surname><given-names>DLM</given-names></name><name><surname>Bagowski</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tip-1 induces filopodia growth and is important for gastrulation movements during zebrafish development</article-title><source>Development, Growth &amp; Differentiation</source><volume>49</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/j.1440-169X.2007.00921.x</pub-id><pub-id pub-id-type="pmid">17394599</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>T</given-names></name><name><surname>Danilchik</surname><given-names>M</given-names></name><name><surname>Thumberger</surname><given-names>T</given-names></name><name><surname>Vick</surname><given-names>P</given-names></name><name><surname>Tisler</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>I</given-names></name><name><surname>Bogusch</surname><given-names>S</given-names></name><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Ulmer</surname><given-names>B</given-names></name><name><surname>Walentek</surname><given-names>P</given-names></name><name><surname>Niesler</surname><given-names>B</given-names></name><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Schweickert</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Serotonin signaling is required for Wnt-dependent GRP specification and leftward flow in <italic>Xenopus</italic></article-title><source>Current Biology</source><volume>22</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2011.11.027</pub-id><pub-id pub-id-type="pmid">22177902</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanon</surname><given-names>I</given-names></name><name><surname>Baylies</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A Twist in fate: evolutionary comparison of Twist structure and function</article-title><source>Gene</source><volume>287</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(01)00893-9</pub-id><pub-id pub-id-type="pmid">11992718</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>YI</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Sepich</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>FG</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation</article-title><source>Genes &amp; Development</source><volume>20</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1101/gad.1374506</pub-id><pub-id pub-id-type="pmid">16391234</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaffer</surname><given-names>CL</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A perspective on cancer cell metastasis</article-title><source>Science</source><volume>331</volume><fpage>1559</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1126/science.1203543</pub-id><pub-id pub-id-type="pmid">21436443</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M-W</given-names></name><name><surname>Hua</surname><given-names>K-T</given-names></name><name><surname>Kao</surname><given-names>H-J</given-names></name><name><surname>Chi</surname><given-names>C-C</given-names></name><name><surname>Wei</surname><given-names>L-H</given-names></name><name><surname>Johansson</surname><given-names>G</given-names></name><name><surname>Shiah</surname><given-names>S-G</given-names></name><name><surname>Chen</surname><given-names>P-S</given-names></name><name><surname>Jeng</surname><given-names>Y-M</given-names></name><name><surname>Cheng</surname><given-names>T-Y</given-names></name><name><surname>Lai</surname><given-names>T-C</given-names></name><name><surname>Chang</surname><given-names>J-S</given-names></name><name><surname>Jan</surname><given-names>Y-H</given-names></name><name><surname>Chien</surname><given-names>M-H</given-names></name><name><surname>Yang</surname><given-names>C-J</given-names></name><name><surname>Huang</surname><given-names>M-S</given-names></name><name><surname>Hsiao</surname><given-names>M</given-names></name><name><surname>Kuo</surname><given-names>M-L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM</article-title><source>Cancer Research</source><volume>70</volume><fpage>7830</fpage><lpage>7840</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0833</pub-id><pub-id pub-id-type="pmid">20940408</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SC</given-names></name><name><surname>Han</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title><italic>Xenopus</italic> Cdc42 regulates convergent extension movements during gastrulation through Wnt/Ca2+ signaling pathway</article-title><source>Developmental Biology</source><volume>244</volume><fpage>342</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1006/dbio.2002.0602</pub-id><pub-id pub-id-type="pmid">11944942</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>RC</given-names></name><name><surname>Latimer</surname><given-names>A</given-names></name><name><surname>Jessen</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Membrane-type 1 matrix metalloproteinase regulates cell migration during zebrafish gastrulation: evidence for an interaction with non-canonical Wnt signaling</article-title><source>Experimental Cell Research</source><volume>314</volume><fpage>2150</fpage><lpage>2162</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2008.03.010</pub-id><pub-id pub-id-type="pmid">18423448</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits       colorectal cancer cell migration and invasion</article-title><source>Oncology Reports</source><volume>29</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.3892/or.2012.2086</pub-id><pub-id pub-id-type="pmid">23076549</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damm</surname><given-names>EW</given-names></name><name><surname>Winklbauer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PDGF-A controls mesoderm cell orientation and radial intercalation during <italic>Xenopus</italic> gastrulation</article-title><source>Development</source><volume>138</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1242/dev.056903</pub-id><pub-id pub-id-type="pmid">21205800</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dongre</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0080-4</pub-id><pub-id pub-id-type="pmid">30459476</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>S</given-names></name><name><surname>Cau</surname><given-names>J</given-names></name><name><surname>de Santa Barbara</surname><given-names>P</given-names></name><name><surname>Bigou</surname><given-names>S</given-names></name><name><surname>Ge</surname><given-names>Q</given-names></name><name><surname>Delsert</surname><given-names>C</given-names></name><name><surname>Morin</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title><italic>Xenopus</italic> p21-activated kinase 5 regulates blastomeres’ adhesive properties during convergent extension movements</article-title><source>Developmental Biology</source><volume>277</volume><fpage>472</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2004.10.005</pub-id><pub-id pub-id-type="pmid">15617688</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felding-Habermann</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Integrin adhesion receptors in tumor metastasis</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>20</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1023/a:1022983000355</pub-id><pub-id pub-id-type="pmid">12741679</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>RI</given-names></name><name><surname>Litzinger</surname><given-names>M</given-names></name><name><surname>Trono</surname><given-names>P</given-names></name><name><surname>Hamilton</surname><given-names>DH</given-names></name><name><surname>Schlom</surname><given-names>J</given-names></name><name><surname>Palena</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1172/JCI38379</pub-id><pub-id pub-id-type="pmid">20071775</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>An</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration</article-title><source>International Journal of Cancer</source><volume>125</volume><fpage>548</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1002/ijc.24428</pub-id><pub-id pub-id-type="pmid">19415746</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunaratne</surname><given-names>A</given-names></name><name><surname>Thai</surname><given-names>BL</given-names></name><name><surname>Di Guglielmo</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Atypical protein kinase C phosphorylates Par6 and facilitates transforming growth factor β-induced epithelial-to-mesenchymal transition</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>874</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1128/MCB.00837-12</pub-id><pub-id pub-id-type="pmid">23249950</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunnarsson</surname><given-names>L</given-names></name><name><surname>Jauhiainen</surname><given-names>A</given-names></name><name><surname>Kristiansson</surname><given-names>E</given-names></name><name><surname>Nerman</surname><given-names>O</given-names></name><name><surname>Larsson</surname><given-names>DGJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evolutionary conservation of human drug targets in organisms used for environmental risk assessments</article-title><source>Environmental Science &amp; Technology</source><volume>42</volume><fpage>5807</fpage><lpage>5813</lpage><pub-id pub-id-type="doi">10.1021/es8005173</pub-id><pub-id pub-id-type="pmid">18754513</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>BH</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>LH</given-names></name><name><surname>Li</surname><given-names>MZ</given-names></name><name><surname>Kung</surname><given-names>HF</given-names></name><name><surname>Song</surname><given-names>LB</given-names></name><name><surname>Zeng</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer</article-title><source>Molecular Cancer</source><volume>10</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-10-10</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habas</surname><given-names>R</given-names></name><name><surname>Dawid</surname><given-names>IB</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation</article-title><source>Genes &amp; Development</source><volume>17</volume><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1101/gad.1022203</pub-id><pub-id pub-id-type="pmid">12533515</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>HT</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice</article-title><source>Biochemical and Biophysical Research Communications</source><volume>422</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.04.123</pub-id><pub-id pub-id-type="pmid">22564736</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwell</surname><given-names>KA</given-names></name><name><surname>Muir</surname><given-names>B</given-names></name><name><surname>Reinhardt</surname><given-names>F</given-names></name><name><surname>Carpenter</surname><given-names>AE</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Spemann organizer gene, Goosecoid, promotes tumor metastasis</article-title><source>PNAS</source><volume>103</volume><fpage>18969</fpage><lpage>18974</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608636103</pub-id><pub-id pub-id-type="pmid">17142318</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>BA</given-names></name><name><surname>Gomez de la Torre Canny</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Slusarski</surname><given-names>DC</given-names></name><name><surname>Freisinger</surname><given-names>CM</given-names></name><name><surname>Dosch</surname><given-names>R</given-names></name><name><surname>Chou</surname><given-names>MM</given-names></name><name><surname>Wagner</surname><given-names>DS</given-names></name><name><surname>Mullins</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A novel role for MAPKAPK2 in morphogenesis during zebrafish development</article-title><source>PLOS Genetics</source><volume>5</volume><elocation-id>e1000413</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000413</pub-id><pub-id pub-id-type="pmid">19282986</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SK</given-names></name><name><surname>Tanegashima</surname><given-names>K</given-names></name><name><surname>Dawid</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>XIer2 is required for convergent extension movements during <italic>Xenopus</italic> development</article-title><source>The International Journal of Developmental Biology</source><volume>55</volume><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1387/ijdb.113288sh</pub-id><pub-id pub-id-type="pmid">22252488</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HJ</given-names></name><name><surname>Liang</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>CT</given-names></name><name><surname>Chung</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pregnenolone stabilizes microtubules and promotes zebrafish embryonic cell movement</article-title><source>Nature</source><volume>439</volume><fpage>480</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nature04436</pub-id><pub-id pub-id-type="pmid">16437115</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>EW</given-names></name><name><surname>Xue</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>JG</given-names></name><name><surname>Guan</surname><given-names>YY</given-names></name><name><surname>Tang</surname><given-names>YB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Vinpocetine inhibits breast cancer cells growth in vitro and in vivo</article-title><source>Apoptosis : An International Journal on Programmed Cell Death</source><volume>17</volume><fpage>1120</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1007/s10495-012-0743-0</pub-id><pub-id pub-id-type="pmid">22729609</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iioka</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>N</given-names></name><name><surname>Kinoshita</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Essential role of MARCKS in cortical actin dynamics during gastrulation movements</article-title><source>The Journal of Cell Biology</source><volume>164</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1083/jcb.200310027</pub-id><pub-id pub-id-type="pmid">14718521</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>YT</given-names></name><name><surname>Gridley</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cell movements during gastrulation: Snail dependent and independent pathways</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>12</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0959-437X(02)00320-9</pub-id><pub-id pub-id-type="pmid">12100887</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Akedo</surname><given-names>H</given-names></name><name><surname>Uehata</surname><given-names>M</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>An essential part for Rho-associated kinase in the transcellular invasion of tumor cells</article-title><source>Nature Medicine</source><volume>5</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/5587</pub-id><pub-id pub-id-type="pmid">9930872</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jechlinger</surname><given-names>M</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Seither</surname><given-names>P</given-names></name><name><surname>Kraut</surname><given-names>N</given-names></name><name><surname>Capodiecci</surname><given-names>P</given-names></name><name><surname>Donovan</surname><given-names>M</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name><name><surname>Grünert</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Autocrine PDGFR signaling promotes mammary cancer metastasis</article-title><source>The Journal of Clinical Investigation</source><volume>116</volume><fpage>1561</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1172/JCI24652</pub-id><pub-id pub-id-type="pmid">16741576</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jopling</surname><given-names>C</given-names></name><name><surname>van Geemen</surname><given-names>D</given-names></name><name><surname>den Hertog</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects</article-title><source>PLOS Genetics</source><volume>3</volume><elocation-id>e225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.0030225</pub-id><pub-id pub-id-type="pmid">18159945</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuno</surname><given-names>Y</given-names></name><name><surname>Hanyu</surname><given-names>A</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Iwase</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>E</given-names></name><name><surname>Ehata</surname><given-names>S</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway</article-title><source>Oncogene</source><volume>27</volume><fpage>6322</fpage><lpage>6333</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.232</pub-id><pub-id pub-id-type="pmid">18663362</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>C</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Cassaday</surname><given-names>R</given-names></name><name><surname>Olomu</surname><given-names>O</given-names></name><name><surname>Mendoza</surname><given-names>A</given-names></name><name><surname>Yeung</surname><given-names>C</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name><name><surname>Helman</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis</article-title><source>Nature Medicine</source><volume>10</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nm982</pub-id><pub-id pub-id-type="pmid">14704791</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H-R</given-names></name><name><surname>Wheeler</surname><given-names>MA</given-names></name><name><surname>Wilson</surname><given-names>CM</given-names></name><name><surname>Iida</surname><given-names>J</given-names></name><name><surname>Eng</surname><given-names>D</given-names></name><name><surname>Simpson</surname><given-names>MA</given-names></name><name><surname>McCarthy</surname><given-names>JB</given-names></name><name><surname>Bullard</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44</article-title><source>Cancer Research</source><volume>64</volume><fpage>4569</fpage><lpage>4576</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0202</pub-id><pub-id pub-id-type="pmid">15231668</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolosionek</surname><given-names>E</given-names></name><name><surname>Savai</surname><given-names>R</given-names></name><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Guenther</surname><given-names>A</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Banat</surname><given-names>GA</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Pullamsetti</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>4751</fpage><lpage>4765</lpage><pub-id pub-id-type="doi">10.1091/mbc.E09-01-0019</pub-id><pub-id pub-id-type="pmid">19759179</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Bone morphogenetic proteins in the early development of zebrafish</article-title><source>The FEBS Journal</source><volume>274</volume><fpage>2960</fpage><lpage>2967</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05838.x</pub-id><pub-id pub-id-type="pmid">17521339</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krens</surname><given-names>SFG</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Lamers</surname><given-names>GEM</given-names></name><name><surname>Meijer</surname><given-names>AH</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Spaink</surname><given-names>HP</given-names></name><name><surname>Snaar-Jagalska</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation</article-title><source>Developmental Biology</source><volume>319</volume><fpage>370</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2008.04.032</pub-id><pub-id pub-id-type="pmid">18514184</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kröger</surname><given-names>C</given-names></name><name><surname>Afeyan</surname><given-names>A</given-names></name><name><surname>Mraz</surname><given-names>J</given-names></name><name><surname>Eaton</surname><given-names>EN</given-names></name><name><surname>Reinhardt</surname><given-names>F</given-names></name><name><surname>Khodor</surname><given-names>YL</given-names></name><name><surname>Thiru</surname><given-names>P</given-names></name><name><surname>Bierie</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells</article-title><source>PNAS</source><volume>116</volume><fpage>7353</fpage><lpage>7362</lpage><pub-id pub-id-type="doi">10.1073/pnas.1812876116</pub-id><pub-id pub-id-type="pmid">30910979</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Khandrika</surname><given-names>L</given-names></name><name><surname>Hwa</surname><given-names>JS</given-names></name><name><surname>Meacham</surname><given-names>RB</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Koul</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity</article-title><source>Cancer Research</source><volume>70</volume><fpage>832</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2918</pub-id><pub-id pub-id-type="pmid">20068172</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>N</given-names></name><name><surname>Fulton</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer</article-title><source>Cancer Research</source><volume>62</volume><fpage>2343</fpage><lpage>2346</lpage><pub-id pub-id-type="pmid">11956094</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusakabe</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The polarity-inducing kinase Par-1 controls <italic>Xenopus</italic> gastrulation in cooperation with 14-3-3 and aPKC</article-title><source>The EMBO Journal</source><volume>23</volume><fpage>4190</fpage><lpage>4201</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600381</pub-id><pub-id pub-id-type="pmid">15343271</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachnit</surname><given-names>M</given-names></name><name><surname>Kur</surname><given-names>E</given-names></name><name><surname>Driever</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Alterations of the cytoskeleton in all three embryonic lineages contribute to the epiboly defect of Pou5f1/Oct4 deficient MZspg zebrafish embryos</article-title><source>Developmental Biology</source><volume>315</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2007.10.008</pub-id><pub-id pub-id-type="pmid">18215655</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latimer</surname><given-names>A</given-names></name><name><surname>Jessen</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Extracellular matrix assembly and organization during zebrafish gastrulation</article-title><source>Matrix Biology</source><volume>29</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2009.10.002</pub-id><pub-id pub-id-type="pmid">19840849</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latinkic</surname><given-names>BV</given-names></name><name><surname>Mercurio</surname><given-names>S</given-names></name><name><surname>Bennett</surname><given-names>B</given-names></name><name><surname>Hirst</surname><given-names>EMA</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Lau</surname><given-names>LF</given-names></name><name><surname>Mohun</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title><italic>Xenopus</italic> Cyr61 regulates gastrulation movements and modulates Wnt signalling</article-title><source>Development</source><volume>130</volume><fpage>2429</fpage><lpage>2441</lpage><pub-id pub-id-type="doi">10.1242/dev.00449</pub-id><pub-id pub-id-type="pmid">12702657</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Sepich</surname><given-names>DS</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Topczewski</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name><name><surname>Hamm</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Essential roles of G{alpha}12/13 signaling in distinct cell behaviors driving zebrafish convergence and extension gastrulation movements</article-title><source>The Journal of Cell Biology</source><volume>169</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1083/jcb.200501104</pub-id><pub-id pub-id-type="pmid">15928205</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Huo</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo</article-title><source>Cancer Immunology, Immunotherapy</source><volume>61</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1135-y</pub-id><pub-id pub-id-type="pmid">22048717</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>V</given-names></name><name><surname>Carvalho</surname><given-names>L</given-names></name><name><surname>Castanon</surname><given-names>I</given-names></name><name><surname>Stockinger</surname><given-names>P</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Heisenberg</surname><given-names>C-P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Identification of regulators of germ layer morphogenesis using proteomics in zebrafish</article-title><source>Journal of Cell Science</source><volume>119</volume><fpage>2073</fpage><lpage>2083</lpage><pub-id pub-id-type="doi">10.1242/jcs.02928</pub-id><pub-id pub-id-type="pmid">16638810</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>L-T</given-names></name><name><surname>Khadka</surname><given-names>DK</given-names></name><name><surname>Mezzacappa</surname><given-names>C</given-names></name><name><surname>Komiya</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Habas</surname><given-names>R</given-names></name><name><surname>Runnels</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TRPM7 regulates gastrulation during vertebrate embryogenesis</article-title><source>Developmental Biology</source><volume>350</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2010.11.034</pub-id><pub-id pub-id-type="pmid">21145885</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>IS</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Kannappan</surname><given-names>V</given-names></name><name><surname>Tawari</surname><given-names>PE</given-names></name><name><surname>Tang</surname><given-names>JZ</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Armesilla</surname><given-names>AL</given-names></name><name><surname>Darling</surname><given-names>JL</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells</article-title><source>British Journal of Cancer</source><volume>109</volume><fpage>1876</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.534</pub-id><pub-id pub-id-type="pmid">24008666</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Blume-Jensen</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>4016</fpage><lpage>4031</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.12.4016-4031.2001</pub-id><pub-id pub-id-type="pmid">11359909</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis</article-title><source>Developmental Cell</source><volume>49</volume><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.04.010</pub-id><pub-id pub-id-type="pmid">31063755</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lue</surname><given-names>H-W</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>RZH</given-names></name><name><surname>Lyles</surname><given-names>R</given-names></name><name><surname>Osunkoya</surname><given-names>AO</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Zayzafoon</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z-R</given-names></name><name><surname>Zhau</surname><given-names>HE</given-names></name><name><surname>Chung</surname><given-names>LWK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e27720</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027720</pub-id><pub-id pub-id-type="pmid">22110740</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TP</given-names></name><name><surname>Ferrer</surname><given-names>CM</given-names></name><name><surname>Jackson</surname><given-names>SR</given-names></name><name><surname>Shahriari</surname><given-names>KS</given-names></name><name><surname>Vosseller</surname><given-names>K</given-names></name><name><surname>Reginato</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>11070</fpage><lpage>11081</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.302547</pub-id><pub-id pub-id-type="pmid">22275356</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machingo</surname><given-names>QJ</given-names></name><name><surname>Fritz</surname><given-names>A</given-names></name><name><surname>Shur</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A beta1,4-galactosyltransferase is required for convergent extension movements in zebrafish</article-title><source>Developmental Biology</source><volume>297</volume><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.05.024</pub-id><pub-id pub-id-type="pmid">16904099</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>G</given-names></name><name><surname>Knowles</surname><given-names>LM</given-names></name><name><surname>Dhir</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name><name><surname>Pilch</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion</article-title><source>Cancer Research</source><volume>70</volume><fpage>4327</fpage><lpage>4334</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3312</pub-id><pub-id pub-id-type="pmid">20501851</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Schwaninger</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Hartwell</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers</article-title><source>PNAS</source><volume>104</volume><fpage>10069</fpage><lpage>10074</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703900104</pub-id><pub-id pub-id-type="pmid">17537911</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marlow</surname><given-names>F</given-names></name><name><surname>Topczewski</surname><given-names>J</given-names></name><name><surname>Sepich</surname><given-names>D</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Zebrafish Rho kinase 2 acts downstream of Wnt11 to mediate cell polarity and effective convergence and extension movements</article-title><source>Current Biology</source><volume>12</volume><fpage>876</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(02)00864-3</pub-id><pub-id pub-id-type="pmid">12062050</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsden</surname><given-names>M</given-names></name><name><surname>DeSimone</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Integrin-ECM interactions regulate cadherin-dependent cell adhesion and are required for convergent extension in <italic>Xenopus</italic></article-title><source>Current Biology</source><volume>13</volume><fpage>1182</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(03)00433-0</pub-id><pub-id pub-id-type="pmid">12867028</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medici</surname><given-names>D</given-names></name><name><surname>Hay</surname><given-names>ED</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name><name><surname>Bronner-Fraser</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Snail and Slug Promote Epithelial-Mesenchymal Transition through β-Catenin–T-Cell Factor-4-dependent Expression of Transforming Growth Factor-β3</article-title><source>Molecular Biology of the Cell</source><volume>19</volume><fpage>4875</fpage><lpage>4887</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-05-0506</pub-id><pub-id pub-id-type="pmid">18799618</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middelbeek</surname><given-names>J</given-names></name><name><surname>Kuipers</surname><given-names>AJ</given-names></name><name><surname>Henneman</surname><given-names>L</given-names></name><name><surname>Visser</surname><given-names>D</given-names></name><name><surname>Eidhof</surname><given-names>I</given-names></name><name><surname>van Horssen</surname><given-names>R</given-names></name><name><surname>Wieringa</surname><given-names>B</given-names></name><name><surname>Canisius</surname><given-names>SV</given-names></name><name><surname>Zwart</surname><given-names>W</given-names></name><name><surname>Wessels</surname><given-names>LF</given-names></name><name><surname>Sweep</surname><given-names>FCGJ</given-names></name><name><surname>Bult</surname><given-names>P</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>van Leeuwen</surname><given-names>FN</given-names></name><name><surname>Jalink</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TRPM7 is required for breast tumor cell metastasis</article-title><source>Cancer Research</source><volume>72</volume><fpage>4250</fpage><lpage>4261</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3863</pub-id><pub-id pub-id-type="pmid">22871386</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyagi</surname><given-names>C</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Yoshizaki</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>STAT3 noncell-autonomously controls planar cell polarity during zebrafish convergence and extension</article-title><source>The Journal of Cell Biology</source><volume>166</volume><fpage>975</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1083/jcb.200403110</pub-id><pub-id pub-id-type="pmid">15452141</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name><name><surname>Kuroiwa</surname><given-names>A</given-names></name><name><surname>Kikuchi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sdf1/Cxcr4 signaling controls the dorsal migration of endodermal cells during zebrafish gastrulation</article-title><source>Development</source><volume>135</volume><fpage>2521</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1242/dev.020107</pub-id><pub-id pub-id-type="pmid">18579679</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montero</surname><given-names>JA</given-names></name><name><surname>Kilian</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Bayliss</surname><given-names>PE</given-names></name><name><surname>Heisenberg</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Phosphoinositide 3-kinase is required for process outgrowth and cell polarization of gastrulating mesendodermal cells</article-title><source>Current Biology</source><volume>13</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(03)00505-0</pub-id><pub-id pub-id-type="pmid">12906787</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>J</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Bundo</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Goitsuka</surname><given-names>R</given-names></name><name><surname>Farrar</surname><given-names>MA</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3</article-title><source>Blood</source><volume>113</volume><fpage>1483</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-07-166355</pub-id><pub-id pub-id-type="pmid">19047679</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>JW</given-names></name><name><surname>Makinoshima</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Novel Zebrafish Model of Metastasis Identifies the HSD11β1 Inhibitor Adrenosterone as a Suppressor of Epithelial-Mesenchymal Transition and Metastatic Dissemination</article-title><source>Molecular Cancer Research</source><volume>18</volume><fpage>477</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-19-0759</pub-id><pub-id pub-id-type="pmid">31748280</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neeb</surname><given-names>A</given-names></name><name><surname>Wallbaum</surname><given-names>S</given-names></name><name><surname>Novac</surname><given-names>N</given-names></name><name><surname>Dukovic-Schulze</surname><given-names>S</given-names></name><name><surname>Scholl</surname><given-names>I</given-names></name><name><surname>Schreiber</surname><given-names>C</given-names></name><name><surname>Schlag</surname><given-names>P</given-names></name><name><surname>Moll</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>U</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients</article-title><source>Oncogene</source><volume>31</volume><fpage>3796</fpage><lpage>3806</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.535</pub-id><pub-id pub-id-type="pmid">22120713</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Metastasis: from dissemination to organ-specific colonization</article-title><source>Nature Reviews. Cancer</source><volume>9</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/nrc2622</pub-id><pub-id pub-id-type="pmid">19308067</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Cozzi</surname><given-names>PJ</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Shigdar</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>PH</given-names></name><name><surname>John</surname><given-names>KH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of the EpCAM (CD326) in prostate cancer metastasis and progression</article-title><source>Cancer Metastasis Reviews</source><volume>31</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1007/s10555-012-9389-1</pub-id><pub-id pub-id-type="pmid">22718399</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>RYJ</given-names></name><name><surname>Jackson</surname><given-names>RA</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EMT: 2016</article-title><source>Cell</source><volume>166</volume><fpage>21</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id><pub-id pub-id-type="pmid">27368099</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Yoshitomi</surname><given-names>H</given-names></name><name><surname>Takano</surname><given-names>S</given-names></name><name><surname>Shida</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Ohtsuka</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>F</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Yoshidome</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer</article-title><source>British Journal of Cancer</source><volume>99</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604473</pub-id><pub-id pub-id-type="pmid">18594526</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Carroll</surname><given-names>D</given-names></name><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>SC</given-names></name><name><surname>Surani</surname><given-names>MA</given-names></name><name><surname>Jenuwein</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The polycomb-group gene Ezh2 is required for early mouse development</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>4330</fpage><lpage>4336</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.13.4330-4336.2001</pub-id><pub-id pub-id-type="pmid">11390661</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>VP</given-names></name><name><surname>Marshall</surname><given-names>AM</given-names></name><name><surname>Hernandez</surname><given-names>LL</given-names></name><name><surname>Buckley</surname><given-names>AR</given-names></name><name><surname>Horseman</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival</article-title><source>Breast Cancer Research</source><volume>11</volume><elocation-id>bcr2448</elocation-id><pub-id pub-id-type="doi">10.1186/bcr2448</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perentes</surname><given-names>JY</given-names></name><name><surname>Kirkpatrick</surname><given-names>ND</given-names></name><name><surname>Nagano</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>EY</given-names></name><name><surname>Shaver</surname><given-names>CM</given-names></name><name><surname>Sgroi</surname><given-names>D</given-names></name><name><surname>Garkavtsev</surname><given-names>I</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors</article-title><source>Cancer Research</source><volume>71</volume><fpage>4527</fpage><lpage>4538</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4376</pub-id><pub-id pub-id-type="pmid">21571860</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>S</given-names></name><name><surname>Milanovic</surname><given-names>M</given-names></name><name><surname>Rossé</surname><given-names>C</given-names></name><name><surname>De Rycker</surname><given-names>M</given-names></name><name><surname>Lachmann</surname><given-names>S</given-names></name><name><surname>Hibbert</surname><given-names>A</given-names></name><name><surname>Kermorgant</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>2381</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1242/jcs.115832</pub-id><pub-id pub-id-type="pmid">23549785</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Baritaki</surname><given-names>S</given-names></name><name><surname>Marathe</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Beach</surname><given-names>S</given-names></name><name><surname>Bazeley</surname><given-names>PS</given-names></name><name><surname>Beshir</surname><given-names>AB</given-names></name><name><surname>Fenteany</surname><given-names>G</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Daignault</surname><given-names>S</given-names></name><name><surname>Al-Mulla</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Bonavida</surname><given-names>B</given-names></name><name><surname>de la Serna</surname><given-names>I</given-names></name><name><surname>Yeung</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>3091</fpage><lpage>3104</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3546</pub-id><pub-id pub-id-type="pmid">22505648</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reymond</surname><given-names>N</given-names></name><name><surname>Im</surname><given-names>JH</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Vega</surname><given-names>FM</given-names></name><name><surname>Borda d’Agua</surname><given-names>B</given-names></name><name><surname>Riou</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>S</given-names></name><name><surname>Valderrama</surname><given-names>F</given-names></name><name><surname>Muschel</surname><given-names>RJ</given-names></name><name><surname>Ridley</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cdc42 promotes transendothelial migration of cancer cells through β1 integrin</article-title><source>The Journal of Cell Biology</source><volume>199</volume><fpage>653</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1083/jcb.201205169</pub-id><pub-id pub-id-type="pmid">23148235</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rombouts</surname><given-names>K</given-names></name><name><surname>Carloni</surname><given-names>V</given-names></name><name><surname>Mello</surname><given-names>T</given-names></name><name><surname>Omenetti</surname><given-names>S</given-names></name><name><surname>Galastri</surname><given-names>S</given-names></name><name><surname>Madiai</surname><given-names>S</given-names></name><name><surname>Galli</surname><given-names>A</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo</article-title><source>Cancer Letters</source><volume>333</volume><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.01.040</pub-id><pub-id pub-id-type="pmid">23376641</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sack</surname><given-names>U</given-names></name><name><surname>Walther</surname><given-names>W</given-names></name><name><surname>Scudiero</surname><given-names>D</given-names></name><name><surname>Selby</surname><given-names>M</given-names></name><name><surname>Kobelt</surname><given-names>D</given-names></name><name><surname>Lemm</surname><given-names>M</given-names></name><name><surname>Fichtner</surname><given-names>I</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Shoemaker</surname><given-names>RH</given-names></name><name><surname>Stein</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer</article-title><source>Journal of the National Cancer Institute</source><volume>103</volume><fpage>1018</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr190</pub-id><pub-id pub-id-type="pmid">21685359</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>V</given-names></name><name><surname>Reversade</surname><given-names>B</given-names></name><name><surname>De Robertis</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The opposing homeobox genes Goosecoid and Vent1/2 self-regulate <italic>Xenopus</italic> patterning</article-title><source>The EMBO Journal</source><volume>26</volume><fpage>2955</fpage><lpage>2965</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601705</pub-id><pub-id pub-id-type="pmid">17525737</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Kuniyasu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Fujiwara</surname><given-names>R</given-names></name><name><surname>Kitayoshi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>E</given-names></name><name><surname>Kato</surname><given-names>D</given-names></name><name><surname>Shinya</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Ohmori</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Serum CD10 is associated with liver metastasis in colorectal cancer</article-title><source>The Journal of Surgical Research</source><volume>192</volume><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2014.05.071</pub-id><pub-id pub-id-type="pmid">24972738</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>K</given-names></name><name><surname>Ibrahim</surname><given-names>H</given-names></name><name><surname>Stodtmeister</surname><given-names>T</given-names></name><name><surname>Winklbauer</surname><given-names>R</given-names></name><name><surname>Niessen</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>An adhesion-independent, aPKC-dependent function for cadherins in morphogenetic movements</article-title><source>Journal of Cell Science</source><volume>122</volume><fpage>2514</fpage><lpage>2523</lpage><pub-id pub-id-type="doi">10.1242/jcs.042796</pub-id><pub-id pub-id-type="pmid">19549688</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Holets</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kinsey</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role of Fyn kinase in signaling associated with epiboly during zebrafish development</article-title><source>Developmental Biology</source><volume>285</volume><fpage>462</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.07.018</pub-id><pub-id pub-id-type="pmid">16112104</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Jian</surname><given-names>K</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer</article-title><source>Tumour Biology</source><volume>34</volume><fpage>1839</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1007/s13277-013-0725-z</pub-id><pub-id pub-id-type="pmid">23526079</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Gangadharan</surname><given-names>B</given-names></name><name><surname>Brass</surname><given-names>LF</given-names></name><name><surname>Ruf</surname><given-names>W</given-names></name><name><surname>Mueller</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis</article-title><source>Molecular Cancer Research</source><volume>2</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">15280447</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Severson</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wedlich</surname><given-names>D</given-names></name><name><surname>Klymkowsky</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Snail2 controls mesodermal BMP/Wnt induction of neural crest</article-title><source>Development</source><volume>138</volume><fpage>3135</fpage><lpage>3145</lpage><pub-id pub-id-type="doi">10.1242/dev.064394</pub-id><pub-id pub-id-type="pmid">21715424</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skalski</surname><given-names>M</given-names></name><name><surname>Alfandari</surname><given-names>D</given-names></name><name><surname>Darribère</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A key function for alphav containing integrins in mesodermal cell migration during Pleurodeles waltl gastrulation</article-title><source>Developmental Biology</source><volume>195</volume><fpage>158</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1006/dbio.1997.8838</pub-id><pub-id pub-id-type="pmid">9520332</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slanchev</surname><given-names>K</given-names></name><name><surname>Carney</surname><given-names>TJ</given-names></name><name><surname>Stemmler</surname><given-names>MP</given-names></name><name><surname>Koschorz</surname><given-names>B</given-names></name><name><surname>Amsterdam</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>H</given-names></name><name><surname>Hammerschmidt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development</article-title><source>PLOS Genetics</source><volume>5</volume><elocation-id>e1000563</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000563</pub-id><pub-id pub-id-type="pmid">19609345</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Conserved patterns of cell movements during vertebrate gastrulation</article-title><source>Current Biology</source><volume>15</volume><fpage>R213</fpage><lpage>R228</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.03.016</pub-id><pub-id pub-id-type="pmid">15797016</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gastrulation in zebrafish -- all just about adhesion?</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>16</volume><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2006.06.009</pub-id><pub-id pub-id-type="pmid">16797963</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Eckerle</surname><given-names>S</given-names></name><name><surname>Onichtchouk</surname><given-names>D</given-names></name><name><surname>Marrs</surname><given-names>JA</given-names></name><name><surname>Nitschke</surname><given-names>R</given-names></name><name><surname>Driever</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pou5f1-dependent EGF expression controls E-cadherin endocytosis, cell adhesion, and zebrafish epiboly movements</article-title><source>Developmental Cell</source><volume>24</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2013.01.016</pub-id><pub-id pub-id-type="pmid">23484854</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaderna</surname><given-names>S</given-names></name><name><surname>Schmalhofer</surname><given-names>O</given-names></name><name><surname>Wahlbuhl</surname><given-names>M</given-names></name><name><surname>Dimmler</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>K</given-names></name><name><surname>Sultan</surname><given-names>A</given-names></name><name><surname>Hlubek</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Strand</surname><given-names>D</given-names></name><name><surname>Eger</surname><given-names>A</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><name><surname>Behrens</surname><given-names>J</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5682</pub-id><pub-id pub-id-type="pmid">18199550</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speirs</surname><given-names>CK</given-names></name><name><surname>Jernigan</surname><given-names>KK</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Cha</surname><given-names>YI</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Sepich</surname><given-names>DS</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Prostaglandin Gbetagamma signaling stimulates gastrulation movements by limiting cell adhesion through Snai1a stabilization</article-title><source>Development</source><volume>137</volume><fpage>1327</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1242/dev.045971</pub-id><pub-id pub-id-type="pmid">20332150</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway</article-title><source>Oncotarget</source><volume>6</volume><fpage>25975</fpage><lpage>25987</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4543</pub-id><pub-id pub-id-type="pmid">26214021</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szilágyi</surname><given-names>G</given-names></name><name><surname>Nagy</surname><given-names>Z</given-names></name><name><surname>Balkay</surname><given-names>L</given-names></name><name><surname>Boros</surname><given-names>I</given-names></name><name><surname>Emri</surname><given-names>M</given-names></name><name><surname>Lehel</surname><given-names>S</given-names></name><name><surname>Márián</surname><given-names>T</given-names></name><name><surname>Molnár</surname><given-names>T</given-names></name><name><surname>Szakáll</surname><given-names>S</given-names></name><name><surname>Trón</surname><given-names>L</given-names></name><name><surname>Bereczki</surname><given-names>D</given-names></name><name><surname>Csiba</surname><given-names>L</given-names></name><name><surname>Fekete</surname><given-names>I</given-names></name><name><surname>Kerényi</surname><given-names>L</given-names></name><name><surname>Galuska</surname><given-names>L</given-names></name><name><surname>Varga</surname><given-names>J</given-names></name><name><surname>Bönöczk</surname><given-names>P</given-names></name><name><surname>Vas</surname><given-names>A</given-names></name><name><surname>Gulyás</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study</article-title><source>Journal of the Neurological Sciences</source><volume>229–230</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2004.11.053</pub-id><pub-id pub-id-type="pmid">15760651</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Xwnt11 is a target of <italic>Xenopus</italic> Brachyury: regulation of gastrulation movements via Dishevelled, but not through the canonical Wnt pathway</article-title><source>Development</source><volume>127</volume><fpage>2227</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.1242/dev.127.10.2227</pub-id><pub-id pub-id-type="pmid">10769246</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Alroy</surname><given-names>J</given-names></name><name><surname>Sahagian</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Imagable 4T1 model for the study of late stage breast cancer</article-title><source>BMC Cancer</source><volume>8</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-8-228</pub-id><pub-id pub-id-type="pmid">18691423</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Acloque</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>RYJ</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Epithelial-Mesenchymal Transitions in Development and Disease</article-title><source>Cell</source><volume>139</volume><fpage>871</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.007</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>WB</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Kinsey</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role of Yes kinase during early zebrafish development</article-title><source>Developmental Biology</source><volume>277</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2004.08.052</pub-id><pub-id pub-id-type="pmid">15572145</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>Y-J</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Hung</surname><given-names>C-M</given-names></name><name><surname>Hou</surname><given-names>P-T</given-names></name><name><surname>Li</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>Y-J</given-names></name><name><surname>Shen</surname><given-names>Y-T</given-names></name><name><surname>Wu</surname><given-names>T-T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The predominant protein arginine methyltransferase PRMT1 is critical for zebrafish convergence and extension during gastrulation</article-title><source>The FEBS Journal</source><volume>278</volume><fpage>905</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08006.x</pub-id><pub-id pub-id-type="pmid">21214862</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epithelial-mesenchymal plasticity in carcinoma metastasis</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>2192</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1101/gad.225334.113</pub-id><pub-id pub-id-type="pmid">24142872</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lugt</surname><given-names>NM</given-names></name><name><surname>Domen</surname><given-names>J</given-names></name><name><surname>Linders</surname><given-names>K</given-names></name><name><surname>van Roon</surname><given-names>M</given-names></name><name><surname>Robanus-Maandag</surname><given-names>E</given-names></name><name><surname>te Riele</surname><given-names>H</given-names></name><name><surname>van der Valk</surname><given-names>M</given-names></name><name><surname>Deschamps</surname><given-names>J</given-names></name><name><surname>Sofroniew</surname><given-names>M</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene</article-title><source>Genes &amp; Development</source><volume>8</volume><fpage>757</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1101/gad.8.7.757</pub-id><pub-id pub-id-type="pmid">7926765</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannier</surname><given-names>C</given-names></name><name><surname>Mock</surname><given-names>K</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Driever</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>18643</fpage><lpage>18659</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.467787</pub-id><pub-id pub-id-type="pmid">23667256</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>FM</given-names></name><name><surname>Ridley</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rho GTPases in cancer cell biology</article-title><source>FEBS Letters</source><volume>582</volume><fpage>2093</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2008.04.039</pub-id><pub-id pub-id-type="pmid">18460342</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincan</surname><given-names>E</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>25</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s10585-008-9156-4</pub-id><pub-id pub-id-type="pmid">18350253</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wander</surname><given-names>SA</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Besser</surname><given-names>AH</given-names></name><name><surname>Hong</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Ince</surname><given-names>TA</given-names></name><name><surname>Milikowski</surname><given-names>C</given-names></name><name><surname>Bishopric</surname><given-names>NH</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Slingerland</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy</article-title><source>Breast Cancer Research and Treatment</source><volume>138</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1007/s10549-012-2389-6</pub-id><pub-id pub-id-type="pmid">23430223</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro</article-title><source>Breast Cancer Research and Treatment</source><volume>89</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s10549-004-1002-z</pub-id><pub-id pub-id-type="pmid">15666191</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Prostaglandins and cancer</article-title><source>Gut</source><volume>55</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.047100</pub-id><pub-id pub-id-type="pmid">16118353</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>DM</given-names></name><name><surname>Teo</surname><given-names>CF</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wloga</surname><given-names>D</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Klonowski</surname><given-names>KD</given-names></name><name><surname>Wells</surname><given-names>L</given-names></name><name><surname>Dougan</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>O-GlcNAc modifications regulate cell survival and epiboly during zebrafish development</article-title><source>BMC Developmental Biology</source><volume>9</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/1471-213X-9-28</pub-id><pub-id pub-id-type="pmid">19383152</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinbach</surname><given-names>EC</given-names></name><name><surname>Garbus</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Mechanism of action of reagents that uncouple oxidative phosphorylation</article-title><source>Nature</source><volume>221</volume><fpage>1016</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1038/2211016a0</pub-id><pub-id pub-id-type="pmid">4180173</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>DR</given-names></name><name><surname>Hurst</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Defining the Hallmarks of Metastasis</article-title><source>Cancer Research</source><volume>79</volume><fpage>3011</fpage><lpage>3027</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0458</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>RJ</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><name><surname>Sealy</surname><given-names>IM</given-names></name><name><surname>Wali</surname><given-names>N</given-names></name><name><surname>Dooley</surname><given-names>CM</given-names></name><name><surname>Digby</surname><given-names>Z</given-names></name><name><surname>Stemple</surname><given-names>DL</given-names></name><name><surname>Murphy</surname><given-names>DN</given-names></name><name><surname>Billis</surname><given-names>K</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Füllgrabe</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>MP</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name><name><surname>Busch-Nentwich</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A high-resolution mRNA expression time course of embryonic development in zebrafish</article-title><source>eLife</source><volume>6</volume><elocation-id>e30860</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.30860</pub-id><pub-id pub-id-type="pmid">29144233</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilm</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>RG</given-names></name><name><surname>Schultheiss</surname><given-names>TM</given-names></name><name><surname>Hogan</surname><given-names>BLM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The forkhead genes, Foxc1 and Foxc2, regulate paraxial versus intermediate mesoderm cell fate</article-title><source>Developmental Biology</source><volume>271</volume><fpage>176</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2004.03.034</pub-id><pub-id pub-id-type="pmid">15196959</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Denning</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration</article-title><source>Molecular Carcinogenesis</source><volume>50</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/mc.20716</pub-id><pub-id pub-id-type="pmid">21480388</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Dillenburg-Pilla</surname><given-names>P</given-names></name><name><surname>Armando</surname><given-names>S</given-names></name><name><surname>Amornphimoltham</surname><given-names>P</given-names></name><name><surname>Simaan</surname><given-names>M</given-names></name><name><surname>Weigert</surname><given-names>R</given-names></name><name><surname>Molinolo</surname><given-names>AA</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells</article-title><source>Science Signaling</source><volume>4</volume><elocation-id>ra60</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2002221</pub-id><pub-id pub-id-type="pmid">21934106</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Miyagi</surname><given-names>C</given-names></name><name><surname>Fukada</surname><given-names>T</given-names></name><name><surname>Kagara</surname><given-names>N</given-names></name><name><surname>Che</surname><given-names>Y-S</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer</article-title><source>Nature</source><volume>429</volume><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1038/nature02545</pub-id><pub-id pub-id-type="pmid">15129296</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Takamura</surname><given-names>M</given-names></name><name><surname>Masugi</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Ohki</surname><given-names>M</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>89</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2009.5</pub-id><pub-id pub-id-type="pmid">19188911</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Dormann</surname><given-names>D</given-names></name><name><surname>Münsterberg</surname><given-names>AE</given-names></name><name><surname>Weijer</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cell movement patterns during gastrulation in the chick are controlled by positive and negative chemotaxis mediated by FGF4 and FGF8</article-title><source>Developmental Cell</source><volume>3</volume><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/s1534-5807(02)00256-3</pub-id><pub-id pub-id-type="pmid">12361604</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Donaher</surname><given-names>JL</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Itzykson</surname><given-names>RA</given-names></name><name><surname>Come</surname><given-names>C</given-names></name><name><surname>Savagner</surname><given-names>P</given-names></name><name><surname>Gitelman</surname><given-names>I</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis</article-title><source>Cell</source><volume>117</volume><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.06.006</pub-id><pub-id pub-id-type="pmid">15210113</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis</article-title><source>Developmental Cell</source><volume>14</volume><fpage>818</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2008.05.009</pub-id><pub-id pub-id-type="pmid">18539112</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Nakamori</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells</article-title><source>Cancer Research</source><volume>59</volume><fpage>2004</fpage><lpage>2010</lpage><pub-id pub-id-type="pmid">10213513</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>T</given-names></name><name><surname>Rindtorff</surname><given-names>N</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt signaling in cancer</article-title><source>Oncogene</source><volume>36</volume><fpage>1461</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.304</pub-id><pub-id pub-id-type="pmid">27617575</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zong</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Elevated β1,4-Galactosyltransferase I in Highly Metastatic Human Lung Cancer Cells</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>12503</fpage><lpage>12516</lpage><pub-id pub-id-type="doi">10.1074/jbc.M413631200</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Korzh</surname><given-names>V</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Low</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>RhoA acts downstream of Wnt5 and Wnt11 to regulate convergence and extension movements by involving effectors Rho kinase and Diaphanous: use of zebrafish as an in vivo model for GTPase signaling</article-title><source>Cellular Signalling</source><volume>18</volume><fpage>359</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2005.05.019</pub-id><pub-id pub-id-type="pmid">16019189</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70151.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Yasuhito</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Mie University</institution><country>Japan</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.03.04.434001" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.04.434001"/></front-stub><body><p>We are so impressed with this new and ambitious concept for chemical screening using zebrafish embryos to find a novel anti-metastasis drug, Pizotifen. We hope many researchers will use this screening system for anti-cancer drug discovery.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70151.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shimada</surname><given-names>Yasuhito</given-names></name><role>Reviewing Editor</role><aff><institution>Mie University</institution><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.04.434001">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.03.04.434001v6">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A chemical screen based on an interruption of zebrafish gastrulation identifies the HTR2C inhibitor Pizotifen as a suppressor of EMT-mediated metastasis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Three reviewers basically agree that your paper should be published in <italic>eLife</italic>. And I also think it is a very unique and interesting paper suitable for <italic>eLife</italic>. However, two reviewers think that additional data are necessary to strengthen your conclusions. I would be very grateful if you could perform these experiments in order to publish your work with more impact.</p><p>Comprehensive analysis using sequencing data is needed to support the concept that human cancer metastasis mimic/recapitulate zebrafish gastrulation. In addition, Pizotifen's functional part needs additional experiments and more supportive data. Details are in the recommendations to the authors.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors need to provide a detailed catalog numbers of the reagents used in this study.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. It is not clear how the authors narrowed down the list from 66 hits to 22 compounds and further why Pizotifen was selected for further study. Can the authors provide additional information or data to justify exclusion of hits. Based on the data the compounds that effect dopamine based signaling would have been a more obvious pathway to study (4/22 hits).</p><p>2. The selection of human cancer cell lines to validate the findings are not clear. Is HTR2C relevant only to the subset of cancer cell lines studied. Analyses of TCGA or other data sets to show relevance of HTR2C gene expression and survival and or metastasis would greatly strengthen the rationale for picking these cell lines. Is HTR2C relevant for metastasis in all cancers or only in breast cancer. Also, it appears in figure 2B that MCF non metastatic breast cancer cells express higher levels of HTR2C than metastatic skin (MDA-MB-435) and lung (PC9) cells.</p><p>3. Some of the data provided does not support the conclusions drawn. For example, In figure 3 C. The luciferase images clearly show that Pizotifen treated mice have smaller tumors while the data in 3 A and B do not support this data. The measurements of tumor volume appear to be taken too early to actually be reproducible, also the data for proliferation and apoptosis was not shown. The authors should provide more data to justify the conclusions drawn.</p><p>4. Figure 5 A, 5B, 5G. The effects shown in the texts are not clearly visible. Can the authors provide higher magnification (40X) images to show differences noted in the text.</p><p>5. In figure 5D or 5H the effect on Pizotifen on ZEB1 or β-catenin reduction is not observed. Does this suggest this compound is effecting EMT and metastasis by other mechanisms?</p><p>6. It is not clear if HTR2C selectively only inhibits ZEB1 mediated metastases or are its effects more general i.e. its expression also effects other EMT regulators for example SNAIL, SLUG and or TWIST expression. Showing the effect of Pizotifen/ HTR2C on other EMT regulators especially the ones above is recommended.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Line 142: Mentioned DRD2 but did not elaborate on it and explain why it wasn't chosen as a target. In addition, please provide the rationale, why authors forgo other drugs, including the two with the strongest effect, Hexachloroghene and Troglitazone, to focus on Pizotifen.</p><p>2. Line 307, please indicate: in which cancer cells is overexpression of HTR1D associated with Wnt-signaling that enables induction of EMT?</p><p>3. Figure 5E and 5G: the figures do not show convincing nuclear accumulation of ß-catenin. Please show zoom in insert figures.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;A chemical screen based on an interruption of zebrafish gastrulation identifies the HTR2C inhibitor Pizotifen as a suppressor of EMT-mediated metastasis&quot; for further consideration by <italic>eLife</italic>. Your revised article has been reviewed by 3 peer reviewers and the evaluation has been overseen by Didier Stainier as the Senior Editor, and a Reviewing Editor.</p><p>We are impressed with Dr. Nakayama's manuscript with a new and ambitious concept for the chemical screening for cancer metastasis using zebrafish embryos. However, two reviewers have requested that the authors clarify the mechanisms related to EMT. I also agree with their opinions because EMT is one of the most important factors for cancer metastasis and is well-studied already. It is very much expected by other researchers and would strengthen your story.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>EMT is just one of the numerous steps of both gastrulation and tumor metastasis, as they mentioned that the transcriptomic data for zebrafish embryo development at the epiboly/gastrulation stage are based on the whole embryos which include all other activities and are not specific to EMT. As far as they observe phenotypic changes of whole embryo and focus on the similarity between gastrulation and metastasis in the 1st screening, what they should analyze in RNA-seq data is &quot;global similarity&quot; but not EMT. While they mentioned that this point is not really an objective of this study, I still feel this is one of the most important point that can be resolved, although they eventually find a drug that affects EMT.</p><p>Insufficiency of mechanistic parts has not been addressed.</p><p>Overall, I didn't feel in the revised manuscript that the authors have addressed many of my concerns, and recommend to resubmit to the other journal.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors have addressed most of the major comments except for Major comment 6. The authors provide no data (only text below) showing expression of SNAIL, SLUG or TWIST in MCF7 cells with and without Pizotifen, or any data from the mouse xenograft experiments. Since the authors emphasize the role of ZEB1 showing that other EMT factors are not affected or not consistently affected would help. At a minimum the authors should add their statement below to the text.</p><p>6. It is not clear if HTR2C selectively only inhibits ZEB1 mediated metastases are its effects more general i.e. its expression also effects other EMT regulators for example SNAIL, SLUG and or TWIST expression. Showing the effect of Pizotifen/ HTR2C on other EMT regulators especially the ones above is recommended.</p><p>Author response: HTR2C-expressing MCF7 cells expressed not only ZEB1 but also Twist1 and SNAIL. In contrast, Pizotifen-treated MDA-MB-231 cells showed decreased expression of ZEB1 and Twist1 compared with that in vehicle-treated the cells. In the primary tumors of Pizotifen-treated mice, only ZEB1 expression was decreased compared with those of vehicle-treated mice.&quot;</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70151.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors need to provide a detailed catalog numbers of the reagents used in this study.</p></disp-quote><p>I added catalog numbers of the reagents used in this study.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. It is not clear how the authors narrowed down the list from 66 hits to 22 compounds and further why Pizotifen was selected for further study. Can the authors provide additional information or data to justify exclusion of hits. Based on the data the compounds that effect dopamine based signaling would have been a more obvious pathway to study (4/22 hits).</p></disp-quote><p>Zebrafish embryo screen identified 78 drugs as epiboly-interrupting drugs. Sixteen of the 78 drugs strongly affected cell viability at concentrations less than 1µM and were not used in the cell motility experiments. The remaining 62 drugs were assayed in Boyden chamber motility experiments. Twenty of the 62 drugs enabled to inhibit cell motility and invasion of MDAMB-231 cells without effecting cell viability and proceeded to next examination. The 42 drugs were passed over.</p><p>Inhibiting Dopamine receptor D2 (DRD2) suppressed metastatic dissemination of human cancer cells in a zebrafish xenografted model. However, overexpression of DRD2 could not induce EMT on MCF7 cells. Therefore, we have stop focusing DRD2. We incorporated this point into discussion part, line 777 to 781.</p><disp-quote content-type="editor-comment"><p>2. The selection of human cancer cell lines to validate the findings are not clear. Is HTR2C relevant only to the subset of cancer cell lines studied. Analyses of TCGA or other data sets to show relevance of HTR2C gene expression and survival and or metastasis would greatly strengthen the rationale for picking these cell lines.</p></disp-quote><p>According to cancer cell line encyclopedia, <italic>HTR2C</italic> mRNA expression is observed in cell lines which are established from embryo carcinoma, ovarian cancer, brain cancer, neuroblastoma, and myeloma. Ectopic expression of HTR2C is observed in not only the human cancer cell lines used in this study but also other cancer cell lines.</p><p>The reason why we select the human cancer cell lines used in this study, is that they are commonly used in an experimental study of metastasis and show metastasis in high frequency when they are xenografted into mice.</p><disp-quote content-type="editor-comment"><p>Is HTR2C relevant for metastasis in all cancers or only in breast cancer.</p></disp-quote><p>Pai et al., Breast Cancer Research 2009 shows that HTR2C expression is correlated with tumor stage of breast cancer patients and is higher in metastatic and Her2/ neu-overexpressing tumors (Vaibhav P Pai et al., 2009). We incorporate this point to main text in line 270-272.</p><disp-quote content-type="editor-comment"><p>Also, it appears in figure 2B that MCF non metastatic breast cancer cells express higher levels of HTR2C than metastatic skin (MDA-MB-435) and lung (PC9) cells.</p></disp-quote><p>Serotonin binds to HTR2C and activates HTR2C-mediated signaling. Biochemically, tryptophan hydroxylase 1 (TPH1) catalyzes amino acid tryptophan and yields serotonin. Serotonin in in vitro condition is provided from either an autocrine production of serotonin in cancer cells or culture media. Figure 5C clearly showed nuclear accumulation of β-catenin and p-GSK-3β were not observed in MCF7 cells. The result suggest serotonin would not exist in culture media and an autocrine production of serotonin would activate HTR2C-mediated signaling. Pai et al., revealed that MDA-MB-231 cells express TPH1 but MCF7 cells not. According to cancer cell line encyclopedia<italic>, TPH1</italic> mRNA expressions in MDAMB-435 and PC9 cells is approximately five and two-fold rather than that in MCF7 cells, respectively. Taken together, both of HTR2C expression and an autocrine production of serotonin by TPH1 would need to activate HTR2C-mediated signaling.</p><disp-quote content-type="editor-comment"><p>3. Some of the data provided does not support the conclusions drawn. For example, In figure 3 C. The luciferase images clearly show that Pizotifen treated mice have smaller tumors while the data in 3 A and B do not support this data. The measurements of tumor volume appear to be taken too early to actually be reproducible, also the data for proliferation and apoptosis was not shown. The authors should provide more data to justify the conclusions drawn.</p></disp-quote><p>4T1 tumors grow aggressively in the primary sites and the tumor sizes often exceed the limits that are allowed in most animal protocols. Therefore, in 4T1 metastasis model, the primary tumors are usually resected at day 10 post inoculation. Following the conventional protocol on the model, we resected primary tumors at day 10 post inoculation. The images of top left and top right of Figure 3C were taken before the resection. In the image of bottom left of Figure 3C, bioluminescence emissions are detected around the mammary fat pad of vehicle-treated mice but the emissions might arise from either the lymph node or unresected primary tumor.</p><p>We have added data of apoptosis status in primary tumor of either vehicle or Pizotifen-treated mice as Figure S4. Proliferation status in primary tumor of either vehicle or Pizotifen-treated mice are indicated in Figure 3B.</p><disp-quote content-type="editor-comment"><p>4. Figure 5 A, 5B, 5G. The effects shown in the texts are not clearly visible. Can the authors provide higher magnification (40X) images to show differences noted in the text.</p></disp-quote><p>We inserted higher magnification images in Figure 5E and 5G. By using three different methods: immunofluorescence images, FACS and western blotting, we demonstrate Pizotifen recovers E-cadherin expression on a part of MDA-MB-231 cells. Immunofluorescence images in Figure 5A point that a part of Pizotifen-treated MDA-MB-231 cells show Ecadherin expression. Higher magnification image in Figure 5A would have missed the point.</p><disp-quote content-type="editor-comment"><p>5. In figure 5D or 5H the effect on Pizotifen on ZEB1 or β-catenin reduction is not observed. Does this suggest this compound is effecting EMT and metastasis by other mechanisms?</p></disp-quote><p>Quantification analyses of western blotting bands in Figure 5H reveals that b-catenin accumulation in the nucleus of Pizotifen-treated MDA-MB-231 cells decreased compared with those of vehicle-treated ones. Similar analyses in Figure 5D shows ZEB1 expression of Pizotifen-treated MDA-MB-231 cells slightly decreased compared with those of vehicle-treated ones. ZEB1 expression was significantly decreased in E-cadherin positive fraction of Pizotifen-treated MDA-MB-231 cells compared with ZEB1 expression in vehicle-treated ones. Therefore, we conclude Pizotifen affects ZEB1 expression.</p><disp-quote content-type="editor-comment"><p>6. It is not clear if HTR2C selectively only inhibits ZEB1 mediated metastases or are its effects more general i.e. its expression also effects other EMT regulators for example SNAIL, SLUG and or TWIST expression. Showing the effect of Pizotifen/ HTR2C on other EMT regulators especially the ones above is recommended.</p></disp-quote><p>HTR2C-expressing MCF7 cells expressed not only ZEB1 but also Twist1 and SNAIL. In contrast, Pizotifen-treated MDA-MB-231 cells showed decreased expression of ZEB1 and Twist1 compared with that in vehicle-treated the cells. In the primary tumors of Pizotifen-treated mice, only ZEB1 expression was decreased compared with those of vehicle-treated mice.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Line 142: Mentioned DRD2 but did not elaborate on it and explain why it wasn't chosen as a target.</p></disp-quote><p>We incorporated this point to discussion part, line 777-781.</p><p>Inhibiting Dopamine receptor D2 (DRD2) suppressed cell invasion and migration of multiple human cancer cell lines in vitro However, overexpression of DRD2 could not induce EMT on MCF7 cells. In contrast, pharmacologic and genetic inhibition of HTR2C suppressed metastatic progression; conversely, overexpression of HTR2C induced EMT. Therefore, we focus on Pizotifen.</p><disp-quote content-type="editor-comment"><p>In addition, please provide the rationale, why authors forgo other drugs, including the two with the strongest effect, Hexachloroghene and Troglitazone, to focus on Pizotifen.</p></disp-quote><p>We incorporated this point to discussion part, line 763-771. We have two reasons why we did not focus on Hexachloroghene. One is that Hexachloroghene strongly inhibited cell invasion and migration of MDA-MB-231 cells but did not affect cell invasion and migration of other cells: MDA-MB-436 and PC9 cells.</p><p>Second is that commercial products including Hexachloroghene killed 15 babies in the</p><p>United States and 39 babies in France in 1972. Even if we could demonstrate</p><p>Hexachloroghene has suppressor effect on metastasis, an issue of the toxic effects might abolish the new discovery. Therefore, we stopped focusing Hexachloroghene.</p><p>We have one reason why we did not focus on Troglitazone. Troglitazone has potential high liver toxicity and leads to drug-induced hepatitis. Once troglitazone was approved by FDA, it was withdrawn from the British market in December 1997, from the United States market in 2000, and from the Japanese market soon afterwards. Even if we could demonstrate Troglitazone has suppressor effect on metastasis, an issue of the toxic effects might abolish the new discovery. Therefore, we stopped focusing Troglitazone.</p><disp-quote content-type="editor-comment"><p>2. Line 307, please indicate: in which cancer cells is overexpression of HTR1D associated with Wnt-signaling that enables induction of EMT?</p></disp-quote><p>This paragraph is changed into &quot;Wnt-signaling plays critical role in inducing EMT. In cancer cells, overexpression of HTR1D is associated with Wnt-signaling&quot;.</p><disp-quote content-type="editor-comment"><p>3. Figure 5E and 5G: the figures do not show convincing nuclear accumulation of ß-catenin. Please show zoom in insert figures.</p></disp-quote><p>We inserted higher magnification images in Figure 5E and 5G.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>EMT is just one of the numerous steps of both gastrulation and tumor metastasis, as they mentioned that the transcriptomic data for zebrafish embryo development at the epiboly/gastrulation stage are based on the whole embryos which include all other activities and are not specific to EMT. As far as they observe phenotypic changes of whole embryo and focus on the similarity between gastrulation and metastasis in the 1st screening, what they should analyze in RNA-seq data is &quot;global similarity&quot; but not EMT. While they mentioned that this point is not really an objective of this study, I still feel this is one of the most important point that can be resolved, although they eventually find a drug that affects EMT.</p></disp-quote><p>We compared the genes expressed in zebrafish gastrulation with the gene related with EMT through performing gene set enrichment analysis (GSEA). The analysis revealed that 50% epiboly, shield and 75%-epiboly stage of zebrafish embryos expressed the genes which promote EMT-mediated metastasis: EMT induction, TGF-β signaling, wnt/β-catenin signaling and Notch signaling (Figure 1—figure supplemental 1). This data demonstrates that a part of genes are commonly expressed between zebrafish gastrulation and EMT-mediated metastasis of human cancer cells.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The authors have addressed most of the major comments except for Major comment 6. The authors provide no data (only text below) showing expression of SNAIL, SLUG or TWIST in MCF7 cells with and without Pizotifen, or any data from the mouse xenograft experiments. Since the authors emphasize the role of ZEB1 showing that other EMT factors are not affected or not consistently affected would help. At a minimum the authors should add their statement below to the text.</p><p>6. It is not clear if HTR2C selectively only inhibits ZEB1 mediated metastases are its effects more general i.e. its expression also effects other EMT regulators for example SNAIL, SLUG and or TWIST expression. Showing the effect of Pizotifen/ HTR2C on other EMT regulators especially the ones above is recommended.</p><p>Author response: HTR2C-expressing MCF7 cells expressed not only ZEB1 but also Twist1 and SNAIL. In contrast, Pizotifen-treated MDA-MB-231 cells showed decreased expression of ZEB1 and Twist1 compared with that in vehicle-treated the cells. In the primary tumors of Pizotifen-treated mice, only ZEB1 expression was decreased compared with those of vehicle-treated mice.&quot;</p></disp-quote><p>We added following statement at line 321-328 and graphic data as Figure 5—figure supplement 4. “HTR2C-expressing MCF7 cells expressed not only ZEB1 but also Twist1 and Snail. […] These results indicate that HTR2C-mediated signaling induced EMT through up-regulation of ZEB1 and blocking HTR2C with Pizotifen induced mesenchymal to epithelial transition through downregulation of ZEB1 (Figure 5—figure supplement 4).”</p></body></sub-article></article>